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Astrocytes are integral components of glutamatergic neurotransmission, providing
essential metabolic processes for neuronal homeostasis and acting as the first line of
defense against xenobiotics crossing the blood brain barrier. Arsenic is a xenobiotic with
widespread natural and industrial prevalence, and has been linked to impaired
neurodevelopment and neuronal death. Given the integrated metabolic nature of
astrocytes and neurons, we sought to explore how arsenic impacts astrocyte metabolism
in order to better understand the mechanisms of xenobiotic toxicity in the mammalian
brain.
We demonstrate that astrocyte viability depends upon de novo glutathione (GSH)
synthesis during arsenic exposure, and sub-lethal arsenic exposure (iAs <10µM)
increased intracellular GSH. Multidrug resistance-associated protein 1 (MRP1) inhibition
increased intracellular arsenic accumulation and sensitized the astrocytes to arsenic. A
24hr time course of intracellular arsenic accumulation indicated that arsenic efflux is
achieved 3hrs following exposure, demonstrating naive and adaptive phases.
U-13C-glucose NMR-based metabolomics revealed that iAs induced an
anaplerotic generation of glutamate via the tricarboxylic acid cycle and its extracellular
release in astrocytes. Quantification of the extracellular glutamate indicated potentially

excitotoxic concentrations were reached (Glu > 20µM), which were not significantly
altered by γ-glutamyl transpeptidase (γGT) or MRP1 inhibition. Excitatory amino acid
transporter 1 and 2 (EAAT1/2) inhibition significantly increased extracellular glutamate
accumulation even in the absence of arsenic.
Mitotoxins rotenone (Rote), paraquat (PQ), or 1-methyl-4-phenylpyridinium
(MPP+) sensitized the astrocytes to arsenic. Inhibition of mitochondrial carbon inputs by
etomoxir (Eto) or UK5099 (UK), or of transamination by aminooxyacetic acid (AOAA),
sensitized astrocytes to arsenic to a similar degree. Eto, UK, and AOAA increased arsenic
accumulation in astrocytes but did not significantly alter extracellular glutamate
accumulation.
This thesis illustrates that mitochondrial metabolism is essential to astrocytes
survival during xenobiotic exposure. Further, the significant efflux of glutamate may
create toxic conditions for neurons. Astrocytes previously have been shown to be
glycolytic, resistant to mitochondrial toxins, and viable in vivo without functional
electron transport chain. These results now demonstrate that mitochondria metabolism is
essential for astrocytes survival under conditions of stress and require us to reassess the
role of mitochondrial metabolism in astrocytes.

iv
TABLE OF CONTENTS
CHAPTER 1: Introduction and Background Information

1

1.1 References

4

CHAPTER 2: Mitochondrial Dysfunction in Glial Cells: Implications for Neuronal
Homeostasis and Survival

6

2.1 Introduction

6

2.2 Glial cell types and their functional roles

7

2.3 Mitochondrial dysfunction in glial cells and its effect on neuronal
function/survival……

11

2.3.1 Cell death

11

2.3.2 Bioenergetics and metabolism

15

2.3.3 Calcium

17

2.3.4 Inflammation

19

2.3.5 Redox homeostasis and detoxification of xenobiotics

21

2.4 Conclusions and perspectives

22

2.5 References

24

CHAPTER 3: Mitochondrial metabolism in astrocytes regulates brain
bioenergetics, neurotransmission and redox balance

29

3.1 Introduction

29

3.2 Astrocytes’ metabolism and bioenergetics: a glycolytic cell

31

v
3.3 Mitochondrial metabolism in astrocytes: Anaplerosis and Cataplerosis

35

3.4 FA oxidation (FAO) in astrocytes: The “missing link”

39

3.5 Mitochondrial Metabolism in Astrocytes and Neurotransmitter Homeostasis

47

3.6 Mitochondrial Metabolism in Astrocytes and Redox balance

53

3.7 Conclusions and perspectives

54

3.8 List of Abbreviations

57

3.9 Acknowledgements

60

3.10 References

61

CHAPTER 4: Astrocytes Depend upon Mitochondria During Arsenic
Exposure

71

4.1 Introduction

71

4.2 Materials and Methods

75

4.3 Results

78

4.3.1 Arsenic Exposure Creates a Reduced Intracellular State

78

4.3.2 Arsenic Exposure Increases Glutamate Synthesis from Glucose

78

4.3.3 Astrocyte Viability is Limited by GSH Synthesis, not GSH Recycling,
during Arsenic Exposure
4.3.4 Astrocyte Arsenic Detoxification is Dependent upon MRP1

80
83

4.3.5 Extracellular Glutamate Accumulates in Astrocyte Cultures Exposed to
Arsenic

83

vi
4.3.6 Extracellular Glutamate Accumulation is not dependent on MRP1 or
ɣGT

85

4.3.7 Extracellular Glutamate Accumulates Independently of Arsenic during
EAAT1/2 Inhibition, but only EAAT1 sensitizes Astrocytes to Arsenic

85

4.3.8 Inhibition of xCT has Minor Sensitizing Effects on Astrocytes to
Arsenic

87

4.3.9 Inhibition of Mitochondria or Transamination Sensitizes Astrocytes to
Arsenic

87

4.3.10 Etomoxir and Arsenic Co-administration Damages Mitochondrial
Respiratory Capacity

88

4.3.11 13C/15N Glutamate NMR Preliminary: Arsenic Doesn’t Alter GSH
Incorporation, but Increases Extracellular Glutamate and Intracellular
Glutamine
4.4 Discussion

91
93

4.4.1 Astrocyte Arsenic Detoxification is Dependent upon GSH
Biosynthesis and MRP1

93

4.4.2 Arsenic Exposure Induces Excitotoxic Glutamate Accumulation
in Astrocyte Cultures

94

4.4.3 Mitochondrial Function is Integral to Astrocyte Viability in the
Presence of Arsenic

96

4.5 Conclusions

101

4.6 References

103

vii
CHAPTER 5: Conclusions and Future Directions

110

5.1 References

116

APPENDIX A: Supplemental Figures

118

viii
List of Figures

Chapter 2
Figure 2.1: Neuronal metabolism, redox homeostasis and signaling are
supported by neighboring glial cells
Figure 2.2: Mitochondrial metabolism and signaling in astrocytes

8
12

Chapter 3
Figure 3.1: Central Carbon Metabolism in Astrocytes

32

Figure 3.2: Mitochondrial Metabolism in Astrocytes

37

Figure 3.3: Neuronal-Astrocytic Metabolic Cooperation

48

Figure 3.4: Fatty Acid Transport into the Mitochondria

50

Chapter 4
Figure 4.1: Intracellular REDOX state of Astrocytes exposed to Arsenic

79

Figure 4.2: 2D-NMR Metabolomics with U-13C-glucose

81

Figure 4.3: Inhibition of GSH synthesis and REDOX cycling during
Arsenite Exposure
Figure 4.4: ICP-MS Time Course of Intracellular Arsenic and MRP1 Inhibition

82
84

Figure 4.5: Extracellular Glutamate and Arsenic Sensitivity Impacted by
EAAT Inhibition
Figure 4.6: Mitochondrial Functions are Essential During Arsenic Exposure

86
89

ix
Figure 4.7: Mito Stress Test during Arsenic and Etomoxir Exposure
Figure 4.8: Essential Tested Metabolic Pathways during Arsenic Exposure

92
102

APPENDIX A
Appendix Figure 1

118

Appendix Figure 2

119

Appendix Figure 3

120

1
CHAPTER 1
INTRODUCTION AND BACKGROUND INFORMATION

Xenobiotics are substances, compounds, or elements that are found at concentrations in
an organism that are not expected to be there. The term xenobiotic is derived from the Greek
words xeno (foreign) and bios (life), and is often used as an encompassing term for anything toxic
to an organism. It should be noted however that xenobiotics are context specific: while the
mitochondrial toxin rotenone is considered a xenobiotic in a mammalian system, it is not
considered a xenobiotic when found within legumes that produce it unless the concentration of
rotenone greatly exceeds the expected concentrations found within that specie. In humans,
environmental xenobiotic exposure has been linked to a variety of neurodegenerative diseases and
irregular neurodevelopment, such as Parkinson’s Disease and Alzheimer’s Disease (see (Bondy,
2016) and (Rock and Patisaul, 2018) for more details). As xenobiotic toxicants are prevalent in
our environment, it is important to understand their effects in order to better treat the symptoms
of their toxicity, particularly when the effects of chronic exposure are not readily observable.
Arsenic is a group 15 metalloid element that is considered a xenobiotic to the mammalian
system and has a widespread and varied natural distribution within the Earth’s crust. Arsenic is
also found in many industrial settings, including waste products from metal smelting, as an n-type
dopant in semiconductors, as a component of alloys and batteries, and as a wood preservative.
Additionally, the toxic properties of arsenic have been exploited in herbicides, pesticides, and
leukemia treatment. Arsenic exposure in humans primarily occurs through ingestion of arsenic
contaminated water or food, and inhalation of arsenic dust, particularly in industrial settings.
Arsenic is highly water soluble, and groundwater sources can be highly contaminated from
natural, industrial, and/or agricultural sources (Nordstrom, 2002;Duker et al., 2005). The danger

2
that can occur from arsenic contaminated water was highlighted during the 1980s in Bangladesh,
where ground water wells created to provide clean water to the population were years later found
to contain high concentrations of arsenic (for an in depth review, see (Chakraborti et al., 2015)).
At the time of assessment, it was estimated that 21 million people had been exposed to water with
arsenic above 50 µg/L (the maximum permissible limit by the World Health Organization
(WHO)), with twice as many above 10 µg/L (the recommended WHO limit, and the limit adopted
by the United States in 2001) (Smith et al., 2000). In 2011, an approximate 43,000 deaths/year in
Bangladesh (5.6% of all deaths) were attributable to arsenic related poisoning and cancers (Sohel
et al., 2009;Flanagan et al., 2012), highlighting the danger of arsenic contamination. Further, in
2010 an estimated 2.1 million Americans are consuming water from wells above the 10 µg/L
limit of the Environmental Protection Agency (EPA).
Arsenic exposure has been found to negatively impact neurodevelopment. Multiple
inverse correlations have been found between intelligence quotient (IQ) parameters and
environmental arsenic exposure during childhood (Rosado et al., 2007;Dong and Su,
2009;Hamadani et al., 2011;Wasserman et al., 2014). Many studies have focused on the effects of
arsenic on neurons, demonstrating neuronal cell death, dysfunction, and malformation during
arsenic exposure in development (Namgung and Xia, 2001;Chattopadhyay et al.,
2002a;Chattopadhyay et al., 2002b;Wang et al., 2010;Kaler et al., 2013). The mitochondria of
neurons are particularly affected by arsenic exposure, which is a prominent source of neuronal
cell death given neuronal dependence upon oxidative phosphorylation (see (Prakash et al., 2016)
for a review, as well as chapters 2 and 3). While the effects of arsenic on neurons have been
extensively studied, far less research has been directed towards the effects of arsenic on the
astrocytes. As reviewed in more detail in chapters 2 and 3, astrocytes envelope the brain
capillaries with their processes, making them the first cell type to contact toxins capable of
passing the blood brain barrier, such as arsenic. Further, astrocytes have a cooperative
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metabolism with neurons, maintain neuronal REDOX homeostasis, neurotransmitter homeostasis
and clearance, and provide neurons with bioenergetic balance with lactate (see chapter 3). A key
aspect of astrocytes is that they are glycolytic, and do not depend on oxidative phosphorylation
(Supplie et al., 2017). This makes astrocytes far more resistant to mitochondrial poisons
compared to their neuronal counterparts (Bolanos et al., 1995;Almeida et al., 2001), and has led
to the astrocyte mitochondria in particular being understudied in xenobiotic toxicity.
Because neurons and astrocytes are highly interconnected cell types, and disruption of
astrocyte functions can impact neurons and neurotransmission, it is important to understand how
a xenobiotic, such as arsenic, impacts the functions of astrocytes to understand how xenobiotics
affect brain functions. This thesis will begin with a review of central nervous system cell types
and signaling, transition into astrocyte metabolic functions with an emphasis on mitochondria,
and conclude with experiments performed to explore how arsenic affects astrocyte metabolism.
The results show the astrocyte is dependent upon de novo glutathione synthesis and multidrug
resistance protein 1 functions during arsenic exposure. Further, the results indicate a shift in
astrocyte metabolism toward the production and extrusion of excitotoxic concentrations of
glutamate, and demonstrate the astrocyte is dependent upon mitochondrial carbon flux,
transamination, and excitatory amino acid transporter 1 activity during arsenic exposure.
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CHAPTER 2
MITOCHONDRIAL DYSFUNCTION IN GLIAL CELLS: IMPLICATIONS FOR
NEURONAL HOMEOSTASIS AND SURVIVAL
(Published November 1 2017 in Toxicology, Vol. 391:109-115)

2.1 Introduction

Mitochondria are involved in a myriad of other processes relevant for cell function
besides energy (ATP) production (Yin et al., 2014), making them more than simply powerhouses
of the cell. Mitochondria are a hub for signaling processes that include the maintenance of
calcium (Ca2+) homeostasis and the formation of signaling molecules and thus, signaling events
(Bonini;Chandel, 2015). For example, cell death progression is well known to be triggered by the
release of mitochondrial pro-death proteins. Alterations in mitochondrial functions are expected
to have important implications for cellular function and disease progression. Correspondingly,
numerous pathological conditions have been connected to mitochondrial dysfunction.

Neuronal cell death in brain disorders (neurodegeneration) and injury (neurotoxicity and
ischemia) has been linked to a variety of alterations in mitochondrial homeostasis/function
including traffic, quality control and turnover, homeostasis (bioenergetics and electron transport)
and signaling (metabolism and Ca2+ handling) (Chaturvedi and Flint Beal, 2013;Yin et al., 2014).
Compared to other cell types, neurons are more dependent on mitochondrial oxidative
phosphorylation (OXPHOS) to fulfill their energy demands. Mitochondrial dysfunction with the
concomitant energy failure and increased generation of reactive oxygen species (ROS) are
considered central to neuronal cell loss in brain disorders because neurons have a limited capacity
to upregulate glycolysis or to counteract oxidative damage (Herrero-Mendez et al.,
2009;Fernandez-Fernandez et al., 2012). As such, research has been primarily directed at
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understanding the causes and consequences of mitochondrial dysfunction in neuronal populations
affected during neurodegeneration or brain injury (Moran et al., 2012;Yin et al., 2014).

While initially considered as accessory cells to neurons, glial cells are now recognized to
be essential for neuronal cell homeostasis, survival and proper brain function and development
(Fernandez-Fernandez et al., 2012;Kubik and Philbert, 2015;Bolanos, 2016). Importantly, genetic
modifications or xenobiotics (i.e. pesticides [rotenone or paraquat], metals [lead, arsenic],
antibiotics and drugs that target the integrity of mitochondrial DNA) recognized to alter
mitochondrial function in neurons are expected to alter mitochondrial function in glial cells as
well (Ballinger;Chan;Meyer et al., 2013;Kubik and Philbert, 2015). Unfortunately, very few
studies have addressed the pathological implications of mitochondrial dysfunction in glial cells
and its consequences in neurological disorders. Herein, we review the current evidence
demonstrating the importance of mitochondrial homeostasis and signaling in glial function and
how their functional deficiency has important implications for brain disorders and injury that lead
to or are a consequence of neuronal cell death.

2.2 Glial cell types and their functional roles

Glial cells can be generally classified as macroglia (astrocytes and oligodendrocytes) or
microglia. Macroglia originate from the embryonic ectoderm, while microglia originate from the
mesoderm and enter the vertebrate brain during embryogenesis. While initially grouped under the
term “glia” (Greek term for glue), it is now clearly established that glial cells regulate a number
of physiological processes required for proper neuronal survival and brain function. Refinement
and revision of counting techniques have demonstrated that while the overall ratio of neurons to
glial varies between different regions in the brain, a ratio of ~1:1 glia to neuron exists in the
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Figure 2.1 Neuronal metabolism, redox homeostasis and signaling are supported by neighboring glial
cells.

(1.1) Glucose and lactate enter the brain through Glut1 (glucose transporter 1) and MCT1
(monocarboxylate transporter 1) transporters in the vascular epithelium. Glucose (Glut3) and lactate
(MCT1 or 2) are uptaken from the extracellular space by neuronal calls to fuel the TCA cycle for the
generation of ATP and biosynthesis of essential molecules.

(1.2) As a component of the blood brain barrier (BBB), astrocytes uptake glucose from the capillary
epithelium via Glut1 as well, converting the majority of pyruvate (Pyr) generated into lactate which is
exported by MCT1. Astrocytes also uptake the neurotransmitter glutamate (Glu) from the synaptic cleft via
EAAT (excitatory amino acid transporters) to be (a) converted into glutamine (Gln), (b) exchanged for
extracellular cystine (Cys) by xCT, (c) feed into the TCA cycle, or (d) for GSH synthesis. Astrocytes form
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(Figure 2.1 Neuronal metabolism, redox homeostasis and signaling are supported by neighboring glial
cells continued)

extended networks with other glia (oligodendrocytes and astrocytes) via gap junctions, sharing nutrients
and molecular components with cells more distal to the capillaries.

(1.3) Astrocytes contribute to the redox state of neuronal cells by exporting GSH via MRP1 which is
broken down by γGT and ApN into its amino acid components to be uptaken and reassembled as GSH in
neuronal cells. Dysfunctional or damaged mitochondrial, likely capable of generating ROS, are transferred
from neurons to astrocytes to be degraded by mitophagy.

(1.4) Oligodendrocytes wrap neuronal projections (myelin sheaths) improving signal conduction and like
astrocytes, have been proposed to shuttle lactate to the neurons.

(1.5) Microglia are activated by a variety of factors, including cytokines, oxidized proteins, and protein
aggregates. Activated microglia migrate to the site of damage and can induce neuronal or oligodendrocyte
cell death through the release of cytokines, and the generation of ROS via NADPH oxidases (NOX) and
nitric oxide synthases (NOS). AA-T, amino acid transporters; LDH1 or 5, lactate dehydrogenase isoform 1
or 5.
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entire human brain, which is significantly smaller than previous estimates (~10:1).
Oligodendrocytes are reported to be the most abundant type of glial cells (45–75%), followed by
astrocytes (19–40%), and microglia (10% or less) (von Bartheld et al., 2016).

Oligodendrocytes are responsible for axon myelination at large membrane extensions,
providing axons with an “insulating coat” that enhances nerve impulse conduction (Figure 2.1.4).
Oligodendrocytes have several extensions that form several internodal segments of myelin
separated by gaps (Ranvier nodes) (Baumann and Pham-Dinh, 2001;Snell, 2010).
Oligodendrocytes are found in both gray and white matter, but are a major fraction of all the cells
in white matter.

Astrocytes are small cells with processes that are radially arranged, and have
considerable molecular, structural, and functional diversity at the regional level. Astrocyte
extensions cover the external surface of brain capillaries (perivascular feet), the synaptic cleft
between the pre-synaptic and the post-synaptic terminals, and the bare segments of axons at the
Ranvier nodes (Figure 2.1.2). Astrocytes also form highly organized domains interconnected via
gap junctions with other astrocytes and oligodendrocytes (Figure 2.1.2). Additionally, astrocytes
regulate neurotransmitter levels in the synaptic cleft, provide neurons with energetic and
antioxidant precursors (Figure 2.1.2), play an important role in neuro/synaptogenesis and tissue
repair, and also regulate blood flow and inflammatory processes by the release of signaling
mediators (Sofroniew and Vinters, 2010).

Microglial cells are resident macrophages distributed throughout the central nervous
system (CNS) (Byrne and Roberts, 2009). As innate immune cells, microglia are activated by
infection, tissue injury, or xenobiotics. Upon activation, microglia cells retract their cytoplasmic
extensions and migrate to the site of injury, where they proliferate and become antigen presenting
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cells. Microglia phagocytose degenerating cells and act as sources of immunoregulatory and
neuromodulatory factors such as cytokines, chemokines and neurotrophic factors. Microglia can
be activated by cell-surface receptors for endotoxins, cytokines, chemokines, misfolded proteins,
serum factors and ATP (Figure 2.1.5). While mild activation is a key adaptive immune response,
continuous activation or overactivation of microglia is thought to contribute to neurodegeneration
(Hanisch and Kettenmann, 2007;Finsen and Owens, 2011;Hanisch, 2013).

2.3 Mitochondrial dysfunction in glial cells and its effect on neuronal function/survival

2.3.1 Cell death

Apoptosis is a ubiquitous homeostatic mechanism critical for the turnover of cells
throughout the lifespan of multi-cellular organisms. However, dysregulation of apoptosis occurs
as either a cause or consequence of distinct pathologies that include neurodegenerative disorders
(Fadeel and Orrenius, 2005). The signaling pathways that regulate the progression of apoptosis
have been extensively characterized and divided in two pathways. Induction of apoptosis via the
extrinsic pathway is triggered by the activation of the death receptors leading to the activation of
initiator caspases. (Lavrik et al., 2005).

The intrinsic mitochondrial pathway of apoptosis is activated by a wide variety of stimuli
that regulate the expression and function of the Bcl-2 (B-cell lymphoma 2) family of (anti or pro)
apoptotic proteins. The BH3-only Bcl-2 family members (Bad, Bid, Bim and NOXA) regulate the
anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xl and Mcl-1) to promote apoptosis. The pro-apoptotic
effector proteins Bax and Bak are sufficient and necessary for inducing the permeabilization of
the outer mitochondrial membrane and the release of Cyt C (Figure 2.2.6). However, the
activation of BH3-only proteins derepresses the direct inhibition of Bax and Bak by anti-
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Figure 2.2 Mitochondrial metabolism and signaling in astrocytes.

(2.1) Glucose in astrocytes is used for glycogenesis, NADPH production through the PPP, or glycolysis.
Astrocytes are highly glycolytic due to the expression of high levels of 6‐phosphofructo‐2‐kinase /
fructose‐2,6‐bisphosphatase‐3 (PFKFB3), whose byproduct fructose‐2,6‐bisphosphate (F2,6P2), is a
positive effector of the glycolytic enzyme 6‐phosphofructo‐1‐kinase (PFK1). In addition, the activity of
PFKFB3 is increased by phosphorylation by 5′‐AMP‐activated protein kinase (AMPK) (Bolanos, 2016).

(2.2) Astrocytes primarily derive ATP from glycolysis rather than oxidative phosphorylation, where
pyruvate is converted to lactate by LDH5 and exported to the extracellular space to be consumed by
neurons.
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(Figure 2.2 Mitochondrial metabolism and signaling in astrocytes continued)

(2.3) Astrocytes carboxylate pyruvate to oxaloacetate (OAA) via pyruvate carboxylase (PC) to regenerate
TCA cycle intermediates. Phosphorylation of pyruvate dehydrogenase (PDH) restricts the conversion of
pyruvate to acetyl-CoA (Ac-CoA). Thus, FAO has been proposed to be the primary contributor of Ac-CoA
to the TCA cycle.

(2.4) α-ketoglutarate (αKG) generated from the TCA cycle can be transported to the cytosol and converted
to Glu by glutamic-oxaloacetic transaminase 1 or aspartate (Asp) aminotransferase (GOT1) as part of the
malate-Asp shuttle. Glu has three central metabolic pathways in astrocytes. 1) Glu can be converted to Gln
by GS and exported to neurons by the sodium-coupled neutral amino acid transporter 3 (SNAT3). 2) Glu is
exchanged via xCT for extracellular cystine that is reduced to Cys. Extracellular Glu can be uptaken back
by astrocytes by EAAT1/2. Finally, 3) Glu, Gly and Cys are precursors of GSH, which is also exported to
neurons via MRP1.

(2.5) The ER acts as a store for intracellular calcium, where the sarco/endoplasmic reticulum calcium ion
ATPase (SERCA) pumps cytosolic Ca2+ into the ER. Ca2+ signaling is tightly regulated by the activation of
IP3R that release Ca2+ from ER stores, as well as by the activation of plasma membrane Ca 2+ channels.
Mitochondria can buffer Ca2+ by its transport across the inner mitochondrial membrane to the matrix via
MCU), while the export is performed by mNCX and mHCX. Mitochondria can also transport Ca 2+ in and
out of the mitochondria via the activation of distinct Ca2+ permeable channels. In the matrix, Ca2+
stimulates TCA carbon flux by binding to PDH, IDH, and αKGDH, increasing the activity of the ETC and
ATP production.

(2.6) Cyt C is held close to the inner mitochondrial membrane by cardiolipin (not shown), acting as a
component of ETC. Dissociation of Cyt C from cardiolipin, through oxidative or enzymatic means, coupled
with permeabilization of the outer mitochondrial membrane by the formation of Bax/Bak oligomeric
channels, allows Cyt C to escape into the cytosol. Cytosolic Cyt C associates with apoptotic protease-
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(Figure 2.2 Mitochondrial metabolism and signaling in astrocytes continued)

activating factor 1 (APAF1), forming the apoptosome and leading to the activation of caspases to initiate
apoptosis. AGC, aspartate-glutamate carrier; CPT1 or 2, carnitine palmitoyltransferase isoform 1 or 2;
MDH1 or 2, malate dehydrogenase isoform 1 or 2; MPC1, mitochondrial pyruvate carrier 1; OGC, 2oxoglutarate (α-ketoglutarate) carrier.
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apoptotic Bcl-2 proteins. Released Cyt C leads to the recruitment of Apaf1 and caspase 9 into a
platform (apoptosome) that activates caspase 9 and subsequently, executioner caspases 3, 6 and 7.
The extrinsic / death receptor pathway can crosstalk to the intrinsic / mitochondrial pathway of
apoptosis by an amplification loop induced by caspase dependent cleavage/activation of Bid
(Green and Llambi, 2015).

While a number of studies have reported the induction of apoptosis in astrocytes and
microglia under different experimental conditions, very little evidence exists about the loss or
degeneration of these glial cells with respect to human disorders. Conversely, oligodendrocytes
are known to degenerate in demyelinating disorders such as multiple sclerosis, and to be affected
directly or indirectly by the majority of known disorders in the CNS including ischemia, trauma
and neurodegeneration. Glutamate/Ca2+ excitotoxicity, inflammation (cytokines) and oxidative
stress are common triggers for oligodendrocyte injury in these pathological situations (Figure
2.1.4). Oligodendrocytes express ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)/kainite receptors whose activation induces Ca2+ overflow and apoptotic cell death
via the intrinsic mitochondrial pathway via activation of Bax and caspase 3 (Figure 2.1.4) (Ruiz
et al., 2010;Sanchez-Gomez et al., 2011). The high lipid and iron content of oligodendrocytes
also makes them susceptible to oxidative damage induced by cytokines (Zhang et al., 2005).

2.3.2 Bioenergetics and metabolism

Neurons are dependent on high rates of OXPHOS to meet their energy requirements, to
maintain and restore ionic gradients, and for the uptake and recycling of neurotransmitters. In
contrast, astrocytes are highly glycolytic (Figure 2.2.1), but a large portion of glucose is
converted to lactate and released to the extracellular space. Interestingly, glucose consumption in
astrocytes exceeds their energy expenditure, which is explained by the astrocytes-neuron lactate
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shuttle hypothesis where lactate is shuttled from astrocytes (and oligodendrocytes) as a fuel for
OXPHOS in neurons (Figure 2.1.1 and 2.2.2) (Belanger et al., 2011;Funfschilling et al.,
2012a;Lee et al., 2012;Morrison et al., 2013). What limits OXPHOS in astrocytes? Recent
studies have demonstrated that the activity of pyruvate dehydrogenase (PDH), which provides a
route of entry for pyruvate into the tricarboxylic acid (TCA or Krebs) cycle, is reduced by its
phosphorylation in astrocytes (Figure 2.1.1 and 2.2.3) (Halim et al., 2010). Interestingly,
astrocytes have the same oxidative capacity as neurons, but are resilient to mitochondrial
dysfunction (Di Monte et al., 1992).

Other carbon sources can fuel OXPHOS in astrocytes. Glutamate can be metabolized
through the TCA cycle, but astrocytes primarily metabolize it to glutamine by the activity of
glutamine synthase (GS) (Figure 2.2.4). However, when the extracellular concentration of
glutamate increases to levels observed during synaptic transmission, the proportion of glutamate
metabolized by the TCA cycle increases as well, while its conversion to glutamine decreases
concomitantly (McKenna, 2013;Schousboe et al., 2014;Nissen et al., 2015). Importantly,
glutamate also exerts a stimulatory effect on glycolysis as well (Pellerin and Magistretti,
1994;Loaiza et al., 2003).

Acetate is also used as a carbon source by astrocytes, but its physiological significance
has not been established (Belanger et al., 2011;Jiang et al., 2013). Astrocytes can oxidize free
fatty acids (FFA) and ketone bodies, but neurons and oligodendrocytes can only use ketone
bodies as these cell types would be highly vulnerable to ROS formation generated by FFA
oxidation due to their high lipid content (Schonfeld and Reiser, 2013;Iglesias et al., 2016).
Twenty percent of total energy expenditure in the brain is linked to FFA oxidation (FAO), which
occurs primarily in astrocytes (Ebert et al., 2003). As mentioned above, astrocytes exhibit high
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rates of OXPHOS (Lovatt et al., 2007), but a larger proportion of astrocyte PDH is
phosphorylated compared to neuronal PDH, inhibiting the conversion of pyruvate to acetyl-CoA
(Halim et al., 2010). Thus, FAO might actually be a major source for acetyl-CoA into the TCA
cycle (Panov et al., 2014) (Figure 2.2.3).

Oligodendrocytes have similar rates of glycolysis compared to astrocytes, but release less
lactate since a larger proportion of pyruvate derived from glucose is metabolized via PDH into
the TCA cycle. Similar to astrocytes, oligodendrocytes can carboxylate pyruvate to oxaloacetate
via pyruvate carboxylase (PC) to replenish TCA intermediates (anaplerosis) or recycle pyruvate
(Figure 2.2.3) (Amaral et al., 2016). In astrocytes however, pyruvate carboxylation also serves to
compensate for the loss of TCA intermediates due to the generation of glutamate and
subsequently glutamine that is then shuttled to neurons (glutamate-glutamine cycle) (Figure 2.1.2
and 2.2.4) (Schousboe et al., 2014). Lactate metabolism in oligodendrocytes has been
demonstrated to participate in oligodendrocyte differentiation and myelination.(Rinholm et al.,
2011). Importantly, mitochondrial respiration / metabolism seems to be primarily involved in
oligodendrocyte differentiation, while glycolysis appears to be sufficient to maintain postmyelinated (differentiated) oligodendrocytes (Funfschilling et al., 2012b). Accordingly,
demyelination disorders linked to mitochondrial dysfunction seem to be primarily linked to
increased oxidative damage and changes in FFA metabolism but not energy failure (Swalwell et
al., 2011;Lin et al., 2012;Viader et al., 2013).

2.3.3 Calcium
Calcium (Ca2+) signaling is tightly coupled to its homeostasis. Ca2+ gradients across
membranes and cellular compartments are established by the activity of Ca2+ pumps /
transporters. The controlled activation of Ca2+ fluxes allows its release and the subsequent
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activation of a diverse array of signal transducers including kinases, enzymes and ion channels.
Mitochondria are now recognized as important Ca2+ reservoirs or sinks. The regulation of Ca2+
signaling is not a simple process of its release and subsequent compartmentalization. Instead, it
involves a highly localized release and controlled diffusion of Ca2+ across intracellular
compartments and in most cases, the coordinated action of more than one Ca2+ reservoir and
release / uptake system. The spatiotemporal complexity of this process is reflected by the
existence of patterns of Ca2+ waves or sparks that are decoded by transducers selectively localized
in different cellular compartments. Sequestration of Ca2+ within the mitochondrial matrix is
partially driven by the negative environment generated by the extrusion of protons (H+) across the
inner mitochondrial membrane by the ETC (Figure 2.2.3). Translocation of Ca2+ into the matrix
is mediated by the mitochondrial Ca2+ uniporter (MCU) in an energy-independent manner
(Figure 2.2.5). Ca2+ release from the mitochondria is mediated by Ca2+ exchangers (the sodium
[Na+)]/Ca2+ [mNCX] and mitochondrial proton [H+]/Ca2+ exchangers [mHCX]), or the opening of
the mitochondrial permeability transition pore under pathological conditions (Figure 2.2.5).
Importantly, mitochondria act as important buffers for Ca2+ release / influx from the endoplasmic
reticulum (ER) and the plasma membrane that contribute to the regulation of Ca2+ signaling
(Figure 2.2.5) (Rizzuto et al., 2012).
Very little is known about the impact of mitochondrial Ca2+ homeostasis on glial
signaling. However, as in other cell types, functional mitochondria in astrocytes and
oligodendrocytes regulates Ca2+ waves generated by the activation of inositol 1,4,5-triphosphate
(IP3) receptors (IP3R) and the release of Ca2+ from the ER (Simpson and Russell, 1996;Boitier et
al., 1999;Smith et al., 2005). Mitochondrial Ca2+ has also been shown to regulate vesicular
glutamate release from astrocytes that modulates synaptic communication and excitability (Reyes
and Parpura, 2008). Ca2+ accumulation in mitochondria also modulates oxidative phosphorylation
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and energy production. PDH activity is regulated by a Ca2+-dependent dephosphorylation, while
Ca2+ binding also regulates α-ketoglutarate (KGDH)- and isocitrate (IDH)-dehydrogenase
activity, which increases NADH levels, electron flow and ATP synthesis (Figure 2.2.5) (Rizzuto
et al., 2012). Accordingly, Ca2+ release from the ER stimulates mitochondrial-dependent energy
production in astrocytes (Wu et al., 2007). Not only do mitochondria regulate Ca2+ accumulation
and dynamics, but also its release. A recent report demonstrated that Ca2+ release via mNCX is
coupled to store-operated Ca2+ entry (triggered by Ca2+ depletion from ER stores) and regulates
astrocytes proliferation and excitotoxic glutamate release (Parnis et al., 2013). In microglia,
mitochondrial Ca2+ influx via the mitochondrial transient receptor potential vanilloid 1 channel
(TRPV1) depolarizes mitochondria resulting in mtROS production, mitogen activated protein
kinase (MAPK) activation, and enhanced migration (Miyake et al., 2015).

2.3.4 Inflammation
Inflammation is a key contributor to most neurological disorders. In a steady “basal”
state, microglia performs continuous surveillance of the CNS, secrete neurotrophic factors, such
as insulin-like growth factor 1 (IGF1), brain-derived neurotrophic factor (BDNF), transforming
growth factor-β (TGFβ) and nerve growth factor (NGF), and promote synapse pruning for
refinement of neuronal circuits during development. Classical activation of microglia (M1)
conveys the production of ROS and nitrogen species (RNS) and the release of pro-inflammatory
cytokines (tumor necrosis factor [TNF] and interleukin-1β [IL-1β]) to promote brain tissue repair
upon injury (removal of cell debris and restoring of tissue integrity) and, upon prolonged
activation, neuronal dysfunction as well. Disease-associated factors such as xenobiotics, protein
aggregates, and damage (DAMPs) or pathogen-associated molecular patterns (PAMPS) can
activate microglia through a variety of surface receptors. These receptors include Toll-like
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receptors (for lipopolysacharide [LPS], oxidized low-density lipoprotein [LDL] and molecules
released by damaged or dead cells including high-mobility group box 1 [HMGB1] and
nucleotides), nucleotide-binding oligomerization domain (Nod)-like receptors (for amyloid
proteins), advanced glycation end-products receptors or RAGE (that are also activated by
HMGB1), and purinergic receptors (for purines and pyrimidines including nucleoside
triphosphates, e.g. ATP) (Hu et al., 2014). Pro-inflammatory cytokines released from microglia
also “activate” astrocytes, which might produce TNF to potentiate microglia activation as well.
As such, co-cultures of microglia and astrocytes produce more neurotoxic factors than either
activated cell type alone (Saijo and Glass, 2011). Whether astrocytes can be activated in the
absence of microglia is still unclear since most studies using primary cultures of astrocytes also
contain at least 5% of microglia that significantly contribute to astrocyte activation (Facci et al.,
2014;Marinelli et al., 2015). The alternative (M2-like) phenotype of microglia is observed to be
induced by transforming growth factor-β (TGFβ), IL-4, IL-6 and IL-10 secreted from glioma cells
(Saijo and Glass, 2011).

Mitochondrial dysfunction triggers inflammatory responses (West). During
inflammation, changes in mitochondrial metabolism contribute to the activation of microglia. The
M1 phenotype of microglia was recently reported to be paralleled by a metabolic switch from
mitochondrial OXPHOS to glycolysis that enhances carbon flux to the PPP (Figure 2.1.5)
(Voloboueva et al., 2013;Gimeno-Bayon et al., 2014;Orihuela et al., 2016). Interestingly,
inhibition of complex I activity activates microglial cells (Shaikh and Nicholson, 2009;Yuan et
al., 2013;Ye et al., 2016), while impairment of mitochondrial fission reduces the production of
pro-inflammatory signals (Park et al., 2013). Induction of the M2-like phenotype results in no
observable changes in mitochondrial oxygen consumption or lactate production (Orihuela et al.,
2016). However, mitochondrial toxins such as 3-nitropropionic acid and rotenone impair the
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transition to the M2 phenotype induced by IL-4 (Ferger et al., 2010). These results suggest that
mitochondrial dysfunction in microglia can exacerbate the pro-inflammatory M1 phenotype and
result in the release of neurotoxic pro-inflammatory cytokines, and enhanced ROS / RNS
formation (Tang and Le, 2016).

2.3.5 Redox homeostasis and detoxification of xenobiotics

In general, neurons have limited defense mechanisms against ROS compared to
astrocytes. This enhanced resistance to oxidative damage in astrocytes is observed despite the fact
that astrocytes have a deficient mitochondrial respiration and increased ROS formation when
compared to neurons (Lopez-Fabuel et al., 2016). A comparative study also demonstrated that
astrocytes are more resistant to oxidative damage than microglia or oligodendrocytes
(Hollensworth et al., 2000). Astrocytes contain higher levels of endogenous antioxidants and
antioxidant systems that include NADPH and G6PD (glucose-6-phosphate dehydrogenase).
Astrocytes’ resistance to oxidative damage is explained by the activation of the antioxidant
response via the nuclear factor erythroid-2-related factor 2 (Nrf2) transcription factor (GarciaNogales et al., 2003;Shih et al., 2003). Both neurons and astrocytes can synthesize GSH, but
neurons depend on the supply of GSH precursors from astrocytes (Figure 2.1.3). GSH is released
from astrocytes via the ATP-binding cassette transporters subfamily C member 1 transporter
(ABCC1, or multidrug-resistance-associated protein 1 [MRP1]) (Hirrlinger and Dringen, 2005).
Extracellular GSH is then degraded by the γ-glutamyl transpeptidase (γGT) to produce l-cysteinel-glycine (CysGly), which is cleaved further by the neuronal aminopeptidase N (ApN) into the
amino acids glycine and cysteine that are taken up by neurons for de novo GSH synthesis (Figure
2.1.3) (Aoyama et al., 2008;Belanger et al., 2011). The glutamate-glutamine cycle might also be
involved in the regulation of the neuronal redox environment by astrocytes since GSH synthesis
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also requires glutamate. The importance of astrocytes for neuronal redox homeostasis was
evidenced by a recent study demonstrating that conditional depletion of astrocytes promotes
neuronal injury by oxidative stress (Schreiner et al., 2015). Astrocytes are also the first line of
defense against xenobiotics entering into the brain since their extensions cover the external
surface of capillaries as part of the blood brain barrier. Detoxification of electrophiles is
dependent the formation of irreversible adducts with GSH that in many cases depends on the
activity of glutathione-S-transferases (GST) and their efflux through MRPs (Dringen et al., 2015).

But what is the role of mitochondria in redox homeostasis in astrocytes and neurons? The
loss of GSH by its export to neurons or due to the detoxification of electrophiles is expected to
prompt astrocytes to replenish GSH precursors. Interestingly, GSH depletion upregulates
mitochondrial activity in astrocytes (Vasquez et al., 2001) and we have recently observed that
mitochondrial OXPHOS is essential for the detoxification of electrophiles via the GSH/MRP
system (manuscript in preparation), but the exact mechanisms that regulate this phenomenon are
still unclear.

2.4 Conclusions and Perspectives

Mitochondrial dysfunction has been widely recognized as central to the pathogenesis of
neurological disorders. However, the majority of current research efforts have been focused on
understanding the causes and consequences of mitochondrial dysfunction in neuronal cells that
rely on OXPHOS to generate energy and are also more sensitive to mitochondrial ROS
formation. Less is known about the functional role of mitochondria in glial cells and its
implications for neuronal survival and brain function. In this work, we have provided an overview
of the role of mitochondria in glial cell function that includes metabolism, redox homeostasis,
Ca2+ signaling, inflammation and cell death. The evidence so far clearly demonstrates the
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importance of mitochondrial health in glial cells and its relevance to neuronal function.
Nevertheless, this review also highlights our limited understanding of mitochondria function in
glial cells and the need for further investigations in this area that is expanding. For example,
recent studies have demonstrated that damaged mitochondria can be transferred from neuronal
axons for their turnover in astrocytes (Davis et al., 2014), and conversely, astrocytes have been
shown to transfer mitochondria to promote neuronal survival (Hayakawa et al., 2016) (Figure
2.1.3). Many questions remain to be answered regarding the role of mitochondrial in neurological
disorders, but it is time for us to think about mitochondrial health and dysfunction in a more
inclusive context outside neuronal cells.
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CHAPTER 3
MITOCHONDRIAL METABOLISM IN ASTROCYTES REGULATES BRAIN
BIOENERGETICS, NEUROTRANSMISSION AND REDOX BALANCE

3.1 Introduction
The central nervous system (CNS) is a complex, integrated structure composed of diverse
cell types. Neurons are highly specialized cells in charge of transmitting, processing, and storing
information and thus have been considered the functional units of the CNS. However, research
within the last few decades has demonstrated critical roles non-neuronal cells play in CNS
function. The non-neuronal cells of the CNS include macroglia (astrocytes, ependymal cells and
oligodendrocytes) and microglia, which support essential functions such as the maintenance of
neurotransmitter communication, metabolism, trophic support, formation of myelin sheath,
wound healing, and immune surveillance (von Bernhardi et al., 2016) .

Astrocytes originate from the neuroectoderm. Recent estimates suggest they account for
between 19-40% of the glial population (with an estimated glial to neuron ratio of ~1:1), and a
strong regional variation within the CNS (von Bartheld et al., 2016). Astrocytes are a
heterogenous population of cells with a diverse array of morphological, functional and molecular
properties (Garcia-Marin et al., 2007). While the cellular identity of astrocytes is determined by
their gene expression profile post-differentiation (intrinsic patterning) (Song et al., 2002;Krencik
et al., 2011), the surrounding environment and neuronal circuitry further shapes, modifies, and
maintains the form and functions of differentiated astrocytes (extrinsic factors) (Koulakoff et al.,
2008;Yang et al., 2009;Farmer et al., 2016;Ben Haim and Rowitch, 2017). Structurally, astrocytes
contain multiple radial processes that create diverse interfaces with other glia, neurons, and
capillary endothelial cells. Astrocytes’ fine processes and endfeet envelope neuronal cell bodies,
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synapses, and blood vessels. In addition, an intracellular interface with other astrocytes or
oligodendrocytes is generated via gap junctions (connexin channels), creating an extensive
interconnected network throughout the brain (Orthmann-Murphy et al., 2008). Gap junctions
exchange ions and small molecules between cells (<1kDa in size) including; inositol triphosphate
(IP3), K+, Ca2+, ATP, glucose, glutamate, glutathione (GSH), and cyclic AMP; highlighting its
signaling and buffering role within the CNS (Niessen et al., 2000;Goldberg et al., 2002;Bedner et
al., 2006;Lapato and Tiwari-Woodruff, 2018).

Astrocytes are involved in a number of processes associated with brain function and
disease progression. Astrocytes are major secretory cells, releasing factors or transmitters
(gliotransmitters) including neurotransmitters (and their precursors), modulators, peptides,
hormones, trophic (growth) factors, and metabolites. Astrocyte secreted factors have been shown
to be involved in synapse formation, function and plasticity, neuronal growth, differentiation and
survival, as well as in the regulation of the vascular tone and blood flow in the brain. Astrocytes
have also been shown to mediate synaptic pruning by phagocytosis (Chung et al., 2015;MacVicar
and Newman, 2015;Verkhratsky et al., 2016).
Astrocytes become “reactive” as a response to pathological conditions or to perturbations
in cellular homeostasis. Astrocyte reactivity is a loose term that primarily refers to an
enlargement in the cell body and processes (hypertrophy), and an increase in the levels of the
glial fibrillary acidic protein (GFAP), that relates to a pathological stimulus in the CNS. Unlike
microglia, reactive astrocytes are not believed to be proliferative outside of conditions of glial
scar formation, which is a specific, irreversible form of astrocyte reactivity. Reactive astrocytes
contribute to the production and release of cytokines and the neuroinflammatory process during
injury and neurodegeneration. Reactive astrocytes should not be confused with activated
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astrocytes, as the latter pertains to astrocyte responses to neurotransmission (Ben Haim et al.,
2015).

Astrocytes can also be considered the master regulators of brain metabolism. In this
thesis chapter, the importance of astrocytes’ metabolism in the regulation of neurotransmitter
recycling and synthesis, central carbon metabolism and bioenergetics, as well as redox
homeostasis and antioxidant/xenobiotic defense is discussed. Our goal is to highlight the
metabolic niche astrocytes fill within overall brain metabolism.
3.2 Astrocytes’ metabolism and bioenergetics: a glycolytic cell

While the mass of the human brain accounts for approximately 2% of total body weight,
its oxidative metabolism accounts for ~20% of the body’s total oxidative metabolism (Rolfe and
Brown, 1997;Attwell and Laughlin, 2001). Most of this oxidative energy (estimated 75-80%) is
utilized at the synapse to maintain and restore ionic gradients, and for the uptake and recycling of
neurotransmitters (Riveros et al., 1986;Wong-Riley, 1989;Attwell and Laughlin, 2001;Hyder et
al., 2013) (Figure 3.3.4). By comparison, the metabolic processes in astrocytes have been
estimated to account for between 5% and 15% of the total ATP expenditure in the brain (Attwell
and Laughlin, 2001;Belanger et al., 2011). Glucose is the primary energy substrate in the adult
brain, however alternate energy sources can fuel brain function. Lactate transport across the
blood-brain barrier (BBB) (Figure 3.3.1) provides ~8%–10% of the brain’s energy requirements
under basal conditions (Boumezbeur et al., 2010), and it has been estimated to supply ~20%–25%
of energy during energy demanding activities (van Hall et al., 2009). As plasma lactate
concentrations rise, lactate uptake in the CNS increases coinciding with a decrease in
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Figure 3.1: Central Carbon Metabolism in Astrocytes
(1.1) In astrocytes, glucose is used via glycolysis as a principal energy source. The PPP creates redox
potential by replenishing the NADPH pool. Glucose storage in glycogen is restricted or transient at most.
Glucose carbons can also be used for cysteine (Cys) (trans-sulfuration, not shown) and glycine (Gly)
synthesis.

(1.2) Pyruvate is the principal end product of glycolysis in astrocytes. Astrocytes convert most pyruvate
into lactate by LDH5 to be export to the extracellular space. Pyruvate also enters the mitochondria (see
Figure 2 for details).
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(Figure 3.1: Central Carbon Metabolism in Astrocytes continued)
(1.3) FAs are sorted by their size: 12 or less carbons can directly enter the mitochondria, 13-22 carbons
pass into the mitochondria through a shuttle (see Figure 2 for details), and 23+ carbons enter peroxisomes
to create shorter FA products through /β-oxidation. The esterification of FAs (ACS) limits their ability to
pass through membranes, and is required for FAO.

(1.4) Peroxisomal /β-oxidation occurs in a similar manner to mitochondrial FAO but, without an ETC,
FADH2 donates its electrons directly to oxygen to create H2O2 that is neutralized by CAT. The fate of
NADH in peroxisomes has yet to be determined. Multiple species of FA transport systems exist within
peroxisomes, each with different affinities for various FA lengths. Exported FAs enter the mitochondria to
complete FAO.

(1.5) Ketone bodies in astrocytes can enter as substrates for mitochondrial metabolism (see Figure 2 for
details) or can be the end product in mitochondrial metabolism that astrocytes export for other cells.

(1.6) Astrocytes utilize glutamate (Glu) for glutamine (Gln) synthesis (Glu-Gln cycle), Cys acquisition
(xCT or EAAT3), and for GSH synthesis, this later exported via (MRP1). In astrocytes, Glu is imported
from the synaptic cleft by EAAT1/2 or derived from transamination of the mitochondrial TCA intermediate
KG by Asp amino transferases (GOT1/2). Glu can also be used to power the malate (Mal)-Asp shuttle
through AGC or Aralar 1, or enter the mitochondria as a substrate for oxidative phosphorylation (see Figure
2 for details).
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glucose uptake (Smith et al., 2003;van Hall et al., 2009). When required, an important pool of
lactate is always available as the extracellular levels of lactate (0.5-1.5 mM) are similar to those
of glucose (Magistretti and Allaman, 2015).

Metabolism in astrocytes and neurons is interconnected, and it has been clearly
demonstrated that neurons depend upon astrocytes for a variety of metabolic processes. The in
vivo energy demands of astrocytes can be fulfilled in the absence of oxidative phosphorylation,
with an observed increase in lactate production in mutants of Cox10 (part of the cytochrome c
oxidase complex and required for complex IV function), indicating that astrocytes are glycolytic
(Figure 3.1.1 and 3.3.2) (Supplie et al., 2017). Glucose has been reported as being the
preferential energy substrate of astrocytes over lactate, though glucose uptake does not match
theoretical bioenergetic output (Bouzier-Sore et al., 2006;Jakoby et al., 2014). Pyruvate entry into
the tricarboxylic acid (TCA or Krebs) cycle (Figure 3.2.1) is limited by a reduced activity of
pyruvate dehydrogenase (PDH) in astrocytes due to phosphorylation (Bouzier-Sore et al.,
2006;Halim et al., 2010;Jakoby et al., 2014) creating a surplus of pyruvate due to the high levels
of glucose consumption (Figure 3.1.2). In contrast to astrocytes, glycolysis in neurons is
restricted by the continuous degradation of 6-phosphofructo-2-kinase/fructose-2, 6bisphosphatase-3 (PFKFB3), which catalyzes the synthesis of fructose-2,6-bisphosphate
(F2,6BP) an allosteric activator of phosphofructokinase 1 (PFK1) (Almeida et al., 2004;HerreroMendez et al., 2009). Accordingly, glucose utilization in neurons is directed to the pentose
phosphate pathway (PPP) in order to regenerate nicotinamide adenine dinucleotide phosphate
(NADPH) for the reductive recycling for GSH upon oxidative stress (Figure 3.3.3) (DelgadoEsteban et al., 2000;Vaughn and Deshmukh, 2008;Herrero-Mendez et al., 2009;Bolanos, 2016).
The astrocyte-neuron lactate shuttle (ANLS) hypothesis states that a large portion of glucose
metabolism in astrocytes is directed to lactate production and this is subsequently shuttled to
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neurons as fuel for oxidative phosphorylation (OXPHOS) (Figure 3.3.2 and 3.3.3) (Pellerin and
Magistretti, 1994;Magistretti and Allaman, 2015;Machler et al., 2016). However, recent studies
also demonstrate that during energy-demanding conditions neurons have the capacity to
upregulate glucose metabolism, and have been used to argue against the ANLS hypothesis
(Figure 3.3.3) (Patel et al., 2014;Lundgaard et al., 2015;Diaz-Garcia et al., 2017).

Astrocytes also store energy in the form of glycogen, which can be broken down to
lactate. Yet due to the limited amount of glycogen stored in astrocytes (∼3 to 12 μmol glycogen
per g of tissue, 1-6% of total glucose (Choi et al., 1999)), its contribution to the maintenance of
either neuronal or astrocyte energy-dependent processes under stress conditions is still unclear
(Bak et al., 2018). There is strong evidence supporting a robust oxidative metabolic capacity in
astrocytes (1/3 of total brain glucose oxidative metabolism and 1/2 of total brain lactate oxidative
metabolism) (Zielke et al., 2009), and even higher transcriptional levels of both glycolytic and
TCA cycle enzymes in astrocytes vs neurons, as well as a high concentration of mitochondria in
astrocyte endfeet (Figure 3.3.6) (Lovatt et al., 2007). Nevertheless, astrocytes deficient in
mitochondrial respiration survive as glycolytic cells, both in vitro and in vivo (Supplie et al.,
2017). What then is the physiological importance of mitochondrial metabolism in astrocytes? We
next discuss the particularities of mitochondrial metabolism in these glial cells and its importance
for neurotransmission and redox balance.

3.3 Mitochondrial metabolism in astrocytes: Anaplerosis and Cataplerosis

Oxidative metabolism in mitochondria is primarily fueled by pyruvate, fatty acids/ketone
bodies, and glutamine/glutamate. Pyruvate generated from glycolysis is actively transported into
the mitochondrial matrix via the mitochondrial pyruvate carrier (MPC1) to be subsequently
decarboxylated and combined with coenzyme A (CoA) (Figure 3.2.1). Oxidative decarboxylation
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of pyruvate to acetyl-CoA is mediated by PDH and is coupled with the reduction of NAD+ to
NADH. Subsequently, citrate synthase catalyzes the condensation of oxaloacetate with acetylCoA to generate citrate. Pyruvate decarboxylation is the primary carbon source for the TCA cycle
and is sufficient to sustain oxidative carbon flux during energy consumption, as the last step in
the cycle regenerates oxaloacetate to be combined further with another acetyl-CoA molecule
generated by PDH (a closed loop) (Figure 3.2.1). However, TCA cycle intermediates also
provide precursors for the biosynthesis of several classes of molecules. TCA intermediates leave
the cycle via cataplerotic reactions linked to biosynthetic processes, while anaplerotic reactions
supplement carbons back into to the TCA cycle. A balance between anaplerosis and cataplerosis
controls the entry and exit of carbons into the TCA cycle, and is essential for biosynthetic
processes (Figure 3.2.1) (Owen et al., 2002).

Pyruvate carboxylase (PC) is a major anaplerotic enzyme in the mitochondria that
generates oxaloacetate from pyruvate in an ATP-dependent manner (Figure 3.2.1), replenishing
carbons lost by the export of oxaloacetate, citrate, and -ketoglutarate (KG) from the TCA
cycle, for gluconeogenesis, fatty acid (FA) synthesis, and amino acid synthesis, respectively
(Figure 3.1.2, 3.1.6 and 3.2.6). In astrocyte gluconeogenesis, oxaloacetate is converted to
phosphoenolpyruvate (PEP) in the mitochondria by phosphoenolpyruvate carboxykinase
(PEPCK2), as cytosolic phosphoenolpyruvate carboxykinase (PEPCK1) activity has not been
detected in the astrocyte cytosolic fractions (Schmoll et al., 1995). While PEP has been shown to
exit mitochondria (Garber and Ballard, 1969;Stark et al., 2009), the precise mechanism has not
been determined, with the citrate isocitrate carrier (CIC) and adenine nucleotide transporter
(ANT) being proposed (Stark and Kibbey, 2014). In the brain, it has been long recognized that
PC is primarily expressed in astrocytes and to a lesser extent in microglia, oligodendrocytes and
ependymal cells (Shank et al., 1985;Murin et al., 2009). However, as mentioned above, PDH
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Figure 3.2: Mitochondrial Metabolism in Astrocytes
(2.1) The astrocyte TCA cycle is principally used for biosynthetic processes, not OXPHOS. Synthesis of
Ac-CoA from pyruvate is limited by the phosphorylation of PDH (P) Cataplerotic reactions of the TCA
cycle are matched by anaplerotic carbon inputs. Anaplerotic inputs in astrocyte include pyruvate
carboxylatyion to OAA, acetyl-CoA (Ac-CoA) and succinyl-CoA (succ-CoA) synthesis from FAO, and
ketolysis Ac-CoA and glutamate, and GABA neurotransmitter synthesis from KG and succinate,
respectively. Astrocyte cataplerotic outputs include KG, malate, and citrate.

(2.2) FAO produces Ac-CoA and propionyl-CoA (Prop-CoA) that are directed to either ketogenesis,
ketolysis, or as anaplerotic input to the TCA cycle. FAO generates a high yield of NADH and FADH 2 (see
2.5).
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(Figure 3.2: Mitochondrial Metabolism in Astrocytes continued)
(2.3) Ketogenesis condenses Ac-CoA to either acetoacetate (AcAc) or β-hydroxybutyrate (ßHB). FAO is
the principal source of ketogenesis in astrocytes. Ketolysis reverses this process, requiring succ-CoA from
either prop-CoA (FAO or BCAA metabolism [not shown]), or the TCA cycle as a driving force.

(2.4) Mitochondrial Glu synthesis and incorporation into the TCA cycle in astrocytes is performed by
transamination (GOT2, ALAT, BCAT) or by deamination (GDH, GLS, GABA-T) of KG allowing
glutamate to act in both cataplerosis and anaplerosis.

(2.5) The astrocyte ETC is not required for survival, and its activity has been reported to be a source of
ROS due to inefficient complex activity and electron transfer. Importantly high yield of NADH and FADH 2
generated from FAO (see 2.2) can increase ROS formation due to the transfer of electrons from FADH 2 to
ETF, creating a backpressure of electrons flowing from complex I.

(2.6) While the outer mitochondrial membrane is fairly permeable, numerous transporters exist on the inner
membrane to facilitate entry and exit of a number of metabolites from the mitochondrial matrix.
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activity in astrocytes is reduced by its phosphorylation and thus an additional carbon source is
proposed to exist to supplement acetyl-CoA to the TCA cycle (Figure 3.2.1) (Halim et al., 2010).
FA oxidation (FAO) has been proposed to be the preferable substrate for acetyl-CoA synthesis in
astrocytes (Figure 3.1.4 and 3.2.2), but the physiological implications are still unclear (Halim et
al., 2010;Adina-Zada et al., 2012;Panov et al., 2014).
3.4 FA oxidation (FAO) in astrocytes: The “missing link”

Ketone bodies are water-soluble molecules derived from FA metabolism in the liver,
supplying energy to peripheral tissues including the brain. Ketone bodies have been shown to be
produced by astrocytes as well (Blazquez et al., 1998;Cullingford et al., 1998;Guzman and
Blazquez, 2001;Thevenet et al., 2016). During starvation up to ~ 70% of the brain’s energy can
be supplied by ketone bodies (Owen et al., 1967). Ketone bodies are produced in the
mitochondria from acetyl-CoA in three sequential steps mediated by: 1) acetyl-CoA
acetyltransferase 1 (ACAT1) also known as acetoacetyl-CoA thiolase or thiolase II (acetyl-CoA
→ acetoacetyl-CoA, a reversible reaction); 2) β-hydroxy-β-methyl glutaryl (HMG)-CoA synthase
(HMCS1, acetoacetyl-CoA → HMG-CoA); and 3) HMG-CoA lyase (HMGCL, HMG-CoA →
Acetoacetate). Acetoacetate (AcAc) is then decarboxylated to acetone or metabolized to βhydroxybutyrate (βHB) via β-hydroxybutyrate dehydrogenase (BDH) (Figure 3.2.3). Ketone
bodies can cross the BBB and plasma membranes via monocarboxylate transporters (MCT1, 2, 4)
(Figure 3.1.5, 3.3.1 and 3.3.4) (Halestrap and Price, 1999;Morris, 2005). At high concentrations,
ketone bodies have been proposed to support basal and activity-dependent needs of neurons and
glutamatergic signaling, while decreasing glucose utilization (Lopes-Cardozo et al.,
1986;Kunnecke et al., 1993;Sibson et al., 1998;Magistretti et al., 1999;Chowdhury et al.,
2014;Courchesne-Loyer et al., 2017). Within the cell, ketone body transport across the
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mitochondrial membrane has not been fully characterized. While the mitochondrial pyruvate
carrier (MPC1) has been implicated in ketone body transport, inhibition of the MPC1 does not
abolish ketone body accumulation in the mitochondria, indicating that an undetermined
transporter system or diffusion is present (Figure 3.2.6) (Paradies and Papa, 1977;Halestrap,
1978;Booth and Clark, 1981;Achanta and Rae, 2017). In mitochondria, ketolysis starts when
BDH converts β-hydroxybutyrate back to acetoacetate, which is activated to acetoacetyl-CoA by
succinyl‐CoA‐3-oxoacid-CoA transferase (SCOT). Acetoacetyl-CoA is then degraded by ACAT1
generating acetyl-CoA that can be incorporated into the TCA cycle (Figure 3.2.3). Neurons,
astrocytes and oligodendroglia have been shown to be fully capable of using ketone bodies as
metabolic fuel in vitro (Chechik et al., 1987).

In addition to ketone bodies, FAs are also energy substrates for the brain, and unlike
ketone bodies, they diffuse across the BBB rather than relying on transport systems for their
influx. The main source of FAs crossing into the brain are non-esterified long-chain FAs
complexed with albumin and circulating lipoproteins (Hamilton and Brunaldi, 2007). Transport
of non-esterified FAs across the BBB is mediated by passive diffusion (FA flip-flop) or by FA
transporters including FA transport proteins (FATP1 and 4, with intrinsic Acyl-CoA synthetase
activity) and the FA translocase (FAT/CD36) (Figure 3.3.1) (Gnaedinger et al., 1988;Purdon et
al., 1997;Hamilton and Brunaldi, 2007;Ouellet et al., 2009;Mitchell et al., 2011). The exact
transport mechanisms that mediate the uptake of FAs into neurons or astrocytes are still unclear.
A recent report suggests that FATP1 and 4 mediate FA uptake in glial cells. Importantly, while
neurons are capable of synthesizing significant amounts of lipids during bioenergetic excess, they
are reported to be dependent on an apolipoprotein E (ApoE) shuttle system to transfer them to
astrocytes to avoid neurodegenerative phenotypes (Figure 3.3.6) (Liu et al., 2015;Liu et al.,
2017). To utilize FAs metabolically (FAO), FAs must be esterified to CoA in an ATP-dependent
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process by acyl-CoA synthetases (ACS), a process that is often linked to, or performed shortly
after, FA transport by FATPs (Figure 3.1.3) (Mashek et al., 2007;Anderson and Stahl, 2013). In
the brain, signaling through peroxisome proliferation activated receptor beta (PPARß,
predominantly expressed in neurons but also glia) increases the expression of ACS2 (BasuModak et al., 1999), in turn increasing the oxidation of exogenously supplied FAs in neurons
(Marszalek et al., 2004). Astrocytes have an increased expression of both PPARα and ACS1
compared to neurons (Basu-Modak et al., 1999), which has been linked to the upregulation of
genes involved in FAO and ketogenic processes (Cullingford et al., 2002). Carnitine
palmitoyltransferase 1a (CPT1a) transfers the acyl groups from esterified FAs (acyl-CoA) to Lcarnitine, producing acylcarnitine esters which are transported across the outer and inner
mitochondrial membranes via the voltage-dependent anion channel (VDAC) and the
carnitine/acylcarnitine translocase (CACT) transport, respectively. Then, CPT2 converts
acylcarnitine back to acyl-CoA in the mitochondrial matrix (Figure 3.3.4) (Houten and Wanders,
2010;Panov et al., 2014;Romano et al., 2017).
In the mitochondria, acyl-CoAs are principally broken down into acetyl-CoA by βoxidation in a series of sequential reactions that include: 1) an initial FAD-dependent
dehydrogenation of acyl-CoAs by acyl-CoA dehydrogenase (ACD) that generates FADH2; 2) a
subsequent hydration step mediated by enoyl-CoA hydratase (ECH) forming 3hydroxy(OH)acyl-CoA; 3) generation of 3-ketoacyl-CoA via 3-OHacyl-CoA dehydrogenase
(HAD) in an NAD+-dependent manner regenerating NADH; and finally 4) cleavage and release
of acetyl-CoA via thiolase I leaving an acyl-CoA two carbon atoms shorter that re-enters the
pathway. The last three steps are carried by a heteroctamer protein complex called the
mitochondrial trifunctional protein (Figure 3.2.2) (Houten and Wanders, 2010;Panov et al.,
2014;Romano et al., 2017). For FAs/acyl-CoAs with odd numbered carbons, β-oxidation will
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yield propionyl-CoA rather than acetyl-CoA from the final carbons of the acyl-CoA. PropionylCoA is converted to succinyl-CoA in an ATP-dependent manner by a series of mitochondrial
enzymes, providing an anaplerotic input to the TCA cycle and acting as a co-substrate in the
ketolytic conversion of acetoacetyl-CoA to acetoacetate by SCOT (Figure 3.2.3). In the event
that the β-carbon of a FA is methylated, -oxidation occurs to remove one carbon unit as formic
acid (formic acid is converted to carbon dioxide (CO2)), shifting the methylated carbon from the β
to  position, allowing β-oxidation to resume. The steps in -oxidation include: 1) hydroxylation
of the -carbon by phytanoyl-CoA hydroxylase (PhyH/Pahx) utilizing the conversion of KG to
succinate as a driving force; 2) decarboxylation by 2-hydroxyphytanoyl-CoA lyase (2-HPCL)
releasing formyl-CoA and a fatty aldehyde; 3) oxidation of the fatty aldehyde by aldehyde
dehydrogenase generating NADH and an acyl-CoA one carbon shorter than the original product
(Jansen and Wanders, 2006).

A large quantity of ATP can be generated from FAO (one molecule of palmitic acid
provides approximately 115 ATPs vs 32 ATPs generated from glucose oxidation). Despite its
high-energy potential, FAs have long been considered a poor energy substrate in the brain. The
brain as a whole was thought to be limited in β-oxidation capacity as thiolase I, ACD and ECH
activities are 0.7%, 50% and 19% that of the heart mitochondria (Yang et al., 1987), though it
must be noted that glial and neuronal forms of the enzymes were not assayed independently
(Figure 3.2.2). While there are three known carnitine palmitoyltransferase 1 (CPT1) isoforms,
CPT1a has a low expression in the whole brain and is not expressed in neurons (Jernberg et al.,
2017), CTP1b is not expressed in the brain (Obici et al., 2003;Lavrentyev et al., 2004), and
CPT1c localizes exclusively to the endoplasmic reticulum in neurons and has not been shown to
participate in FAO (Wolfgang et al., 2006;Sierra et al., 2008) but has been implicated in ROS
management (Lee and Wolfgang, 2012). Lower CPT1a expression and activity restricts
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mitochondrial oxidation of FAs (Bird et al., 1985), except for those with 12 or fewer carbons,
which can passively diffuse across the mitochondrial inner membrane (Figure 3.1.3, 3.2.2). Yet
the brain has been demonstrated to metabolize carbons from FAs in vivo, accounting for ~20% of
the total acetyl-CoA pool when labeled octanoate is supplied to the bloodstream (Ebert et al.,
2003).This is believed to occur predominantly in astrocytes, based on comparisons of astrocytes,
oligodendrocytes and neurons in primary cultures (Edmond et al., 1987).

Astrocytes have a high buffering capacity against ROS compared to neurons (Sun et al.,
2006), and FAO is proposed to induce higher amounts of ROS formation. One cycle of βoxidation generates one molecule of FADH2 and NADH, increasing the total FADH2/NADH ratio
per acetyl-CoA created compared to glycolysis (Figure 3.2.2). When ACD transfers electrons
from acyl-CoA to FAD, it is coupled to the subsequent transfer of electrons from the resultant
FADH2 to the electron transferring flavoprotein (ETF). The follow-up transfer of electrons from
ETF to ubiquinone by ETF dehydrogenase creates a backpressure of electrons flowing through
complex I (donated from NADH) and complex II (donated from succinate) to ubiquinone that
enhances the probability of leakage and formation of ROS (Figure 3.2.5). Thus, it has been
proposed that restricting FAO protects neurons against oxidative damage beyond the stages of
development (Schonfeld and Reiser, 2013;2017). In the brain, inhibition of FAO by methyl
palmoxirate has been shown to reduce the concentrations of non-enzymatically oxidized
metabolites derived from poly-unsaturated fatty acid (PUFA), indicating that ROS are being
generated from FAO (Chen et al., 2014).

However, mechanism of ROS generation from FA substrates is not universal, and
depends upon the length and structure of the FA. Very long chain FAs (VLCFAs) that are not
esterified have been shown to integrate into artificial phospholipid bilayers, desorpting at slower
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rates than shorter fatty acids and disrupting membrane fluidity (Ho et al., 1995). This integration
and disruption by VLCFAs has been shown to occur in the inner mitochondrial membrane,
decreasing the membrane potential by protonophoric activity, and reducing ROS generated from
reverse electron transport (RET) (Hein et al., 2008). The protonophoric property, and its resulting
decrease in ROS from hyperpolarization, has been demonstrated in medium chain FAs
(MCFAs)(Korshunov et al., 1998), long chain FAs (LCFAs), and branched chain FAs (Schonfeld
and Wojtczak, 2007). This protonophoric capacity of FAs decreases as the length of the FA
decreases (Schonfeld and Wojtczak, 2016), while branched FAs such as phytanic acid show an
increased protonophoric activity compared to their straight chain FA counterparts (Komen et al.,
2007;Schonfeld and Reiser, 2016). Additionally, application of carnitine esters as substrates
demonstrated that RET was not occurring in the mitochondria, furthering that RET is not a
prominent form of ROS production during FAO (Schonfeld et al., 2010).

While protonophoric properties of FAs can mitigate the effects of hyperpolarization/RET,
FAs can promote ROS generated through forward electron transport and by interfering with
electron transport. Isolated mitochondria increased ROS production proportionally to FA
exposure in the presence of the recoupling agent carboxyatractyloside (Schonfeld and Wojtczak,
2007) and during uncoupling with CCCP (Cocco et al., 1999), indicating that ROS was being
generated independently of the protonophoric effects. Interestingly, branched phytanic acid and
poly unsaturated arachidonic acid demonstrated stronger ROS effects than unbranched saturated
FAs in the aforementioned studies (Cocco et al., 1999;Schonfeld and Wojtczak, 2007).
Mitochondria exposed to low concentrations of palmitoylcarnitine were also found to generate
ROS while maintaining membrane potential, with rotenone (complex I inhibition) having
minimal effect on ROS while antimycin (complex III inhibition) dramatically increased ROS
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(Seifert et al., 2010). As described in (Schonfeld and Wojtczak, 2008), despite the evidence of
electron transfer interference by FAs, the mechanism is not well understood.

In the brain, FAO occurs primarily in astrocytes (Edmond et al., 1987;Auestad et al.,
1991;Schonfeld and Reiser, 2013). While both astrocytes and oligodendrocytes uptake saturated
and unsaturated FAs (Hofmann et al., 2017), CTP1a seems to be found primarily in astrocytes
and neural progenitor cells, while absent in neurons, microglia, and oligodendrocytes (Jernberg et
al., 2017). As such, carnitine deficiency causes a metabolic encephalopathy that is characterized
by astrocytic swelling and mitochondrial expansion, corroborating that FAO is an essential
metabolic component of astrocytic function (Kimura and Amemiya, 1990;Calabrese et al.,
2005;Jones et al., 2010). CPT1a activity is negatively regulated by malonyl-CoA, a molecule
synthesized by acetyl-CoA carboxylase (ACC) from cytosolic acetyl-CoA. Malonyl-CoA is also a
principal component of fatty acid synthesis, making this molecule the regulator of FAO and
lipogenesis (Foster, 2012). ACC is inhibited by phosphorylation via the energy sensor adenosine
monophosphate (AMP)-activated protein kinase (AMPK), which links energy deficiency with
mitochondrial β-oxidation (Figure 3.3.4). Recurrent low glucose exposure has been shown to
activate AMPK and increase FAO dependency in astrocytes (Weightman Potter et al., 2019). In
another study, astrocyte activation with ciliary neurotrophic factor (CNTF) was also shown to
activate AMPK and increases β-oxidation and ketolysis (Escartin et al., 2007). In contrast, upon
hypoxic conditions or high concentrations of FAs, ketogenesis is induced in astrocytes and this is
regulated as well by AMPK signaling (Blazquez et al., 1999;Takahashi et al., 2014).

Peroxisomes are located throughout the brain but are primarily found in astrocytes and
oligodendrocytes (Troffer-Charlier et al., 1998). FAs with more than 22 carbons cannot be
transported into the mitochondria via the carnitine shuttle and thus, are broken down first by
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peroxisomes. As in mitochondria, fatty acids must be esterified to CoA before undergoing FAO
in peroxisomes. (Figure 3.1.4 and 3.3.4). Because peroxisomes lack an ETC, electrons from
FADH2 are transferred directly to O2 creating H2O2 that is scavenged by catalase (CAT). Within
the peroxisome, FAs are shortened to acetyl-CoA, propionyl-CoA, and a wide range of long,
medium, and short chain FAs (LCFAs/MCFAs/SCFAs) of 22 carbons or less. A variety of export
systems exist within the peroxisomes, each with different affinities for different lengths of FAs,
including carnitine-transferases (carnitine acetyltransferases (CRATs), carnitine
octanoyltransferases (CROTs)), and thiolases (acyl-CoA thioesterases (ACOTs)) transport
systems (Figure 3.1.4) (Antonenkov and Hiltunen, 2012). Additionally, peroxisomes have been
shown to possess ketogenic enzymes, implicating peroxisomes as another potential source of
ketone bodies and cholesterol (Hovik et al., 1991;Antonenkov et al., 2000;Olivier et al., 2000).
Dysfunction of peroxisomal processes has been linked to demyelination, oxidative stress,
inflammation, cell death, and abnormalities in neuronal migration and differentiation (Trompier
et al., 2014). Defects in the ATP binding cassette subfamily D member 1 (ABCD1) transporter
that translocates very LCFAs into peroxisomes (Figure 3.1.4), leads to the accumulation of these
fats in cells and tissues. VLCFAs and branched chain FAs can interfere directly with the ETC by
opening the permeability transition pore, disrupting calcium balance and depolarizing the
mitochondria (Hein et al., 2008;Kruska et al., 2015;Schonfeld and Reiser, 2016). LCFAs (13 to
21 carbons) activate peroxisome proliferator-activated receptors, transcription factors that
stimulate both β-oxidation and ketogenesis as well as mitochondrial and peroxisome biogenesis.
Recent reports have also demonstrated that peroxisome biogenesis requires the generation of preperoxisomes from mitochondrial derived vesicles (Sugiura et al., 2017).

47
3.5 Mitochondrial Metabolism in Astrocytes and Neurotransmitter Homeostasis

Astrocyte processes extending to synaptic clefts play an important role in regulating
synaptic transmission, particularly glutamatergic signaling. After its vesicle-mediated release, the
excitatory neurotransmitter glutamate is taken from the synaptic cleft by astrocytes in a Na+
dependent manner via the excitatory amino acid transporters EAAT1 (glutamate aspartate
transporter, GLAST) or EAAT2 (glutamate transporter 1, GLT-1) (Figure 3.3.4). In the cytosol,
glutamate is then converted into non-excitatory glutamine via glutamine synthetase (GS), and
transferred back to neurons via the Na+-coupled neutral amino acid transporters (SNATs) to be
converted back into glutamate in neurons via phosphate-activated glutaminase (PAG) (Figure
3.3.4) (Norenberg and Martinez-Hernandez, 1979;Anderson and Swanson, 2000;Schousboe et al.,
2013;Leke and Schousboe, 2016). In astrocytes, despite the presence of a weak mitochondrial
targeting sequence, GS is localized in the cytosol because the mitochondrial membrane potential
is not negative enough to drive GS into the mitochondria (Figure 3.1.6 and 3.3.2) (Matthews et
al., 2010). Neurons lack PC activity (Yu et al., 1983), restricting their ability to replenish TCA
intermediates lost during neurotransmitter release (anaplerotic reaction). Thus, the glutamateglutamine cycle between neurons and astrocytes, not only terminates/modulates glutamatergic
signaling, preventing excitotoxicity triggered by excessive or prolonged exposure to glutamate,
but it also replenishes the neurotransmitter pool in neurons (Belanger et al., 2011) (Figure 3.3.4).

Not all the glutamate taken from the synaptic cleft by astrocytes becomes glutamine.
There is evidence that a significant portion is incorporated into the TCA cycle via oxidative
metabolism (Figure 3.2.4). Glutamate transport into the mitochondria is mediated via the
aspartate/glutamate carrier antiporter (AGC or Aralar 1) or via the glutamate carrier (GC1 or
SLC25A22), a symporter for glutamate and protons (H+). Controversy still exists about the
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Figure 3.3: Neuronal-Astrocytic Metabolic Cooperation
(3.1) GLUTs (glucose), MCTs (Lactate and ketone bodies), and FATPs (fatty acids) transporters facilitate
the transport of carbon sources across the BBB.

(3.2) Astrocytes utilize glucose for the production of ATP (glycolysis), regeneration of NADPH (PPP), and
to feed mitochondrial biosynthetic processes. Astrocytes synthesize and export GSH (MRP1), lactate
(MCT1/4), ketone bodies (MCT1/2), and Gln (at glutamatergic SNAT5 or GABAergic SNAT3 synapses)
that can be utilized by neurons for energy production and synthesis of neurotransmitters.

(3.3) Neurons utilize glucose primarily for the regeneration of NADPH (PPP), with some studies
suggesting that glycolysis can be upregulated during energy-demanding conditions. Lactate and ketone
bodies are used in ATP production (OXPHOS). Neurons import GSH precursors from
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(Figure 3.3: Neuronal-Astrocytic Metabolic Cooperation continued)
astrocytes via EAATs and GlyT1, lactate and ketone bodies via MCT1/2, and Gln through SNAT2/7
(SNAT1/7 in GABAergic neurons).

(3.4) Upon their release into the synaptic cleft Glu and GABA neurotransmitters can be uptaken into
neurons via EAATs and the GABA transporter 1 (GAT1). However, astrocytes have a higher capacity to
uptake and metabolize these neurotransmitters. In astrocytes, GABA is metabolized in the mitochondria
(see Figure 2.4). Glu is taken in by astrocytes (EAAT1/2), converted to Gln (GS), and exported (SNAT5)
for neuronal uptake (SNAT7). In the neurons, Gln is converted to Glu via PAG and then Glu can be
converted to GABA via glutamate decarboxylase (GAD). Neurotransmitters are subsequently loaded into
vesicles via vesicular transporters (VGLUT or VGAT), which do not require ATP per se, but their activity
is coupled to that of the vacuolar H+ ATPase. Na+/K+ ATPases maintain the electrochemical gradient
required to maintain neuronal excitability (not shown) and in astrocytes, essential to drive neurotransmitter
uptake.

(3.5) During periods of excess Ac-CoA lipid synthesis is initiated and transferred into lipid droplets. Lipids
are then transported to astrocytes in an apolipoprotein D/E dependent manner, and taken in by fatty acid
transporter proteins 1 and 4 (FATP1 and 4).

(3.6) In astrocytes, mitochondria co-localize on the plasma membrane with EAAT1/2, Na+/K+ ATPases,
and glycolytic enzymes.
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Figure 3.4: Fatty Acid Transport into the Mitochondria
(4.1) Coenzyme A thioesters (Acyl-CoAs) cannot cross mitochondrial membranes. CPT1a facilitates the
transfer of the acyl group from CoA to carnitine. Acyl-carnitines are permeable to the outer mitochondrial
membrane, but not the inner mitochondrial membrane, requiring the transport via carnitine-acylcarnitine
translocase (CACT) to reach the mitochondrial matrix. Once in the matrix, CPT2 converts the acylcarnitine back to an acyl-CoA, which can then undergo FAO (see Figure 2.2). The released carnitine is then
transported back across the inner mitochondrial membrane by CACT to be reused in the cytosol.
(4.2) Non-esterified fatty acids (NEFAs) of 12 or less carbons do not require the carnitine shuttle system,
and can diffuse across both mitochondrial membranes. However, they still require esterification to CoA by
mitochondrial ACS before they can be metabolized by FAO.
(4.3) The carnitine shuttle system is regulated by malonyl-CoA, a precursor to fatty acid synthesis which
also inhibits CPT1a activity. Malonyl-CoA is principally produced from citrate that is broken into OAA
and acetyl-CoA in the cytosol by ATP citrate lyase (ACL). The released acetyl-CoA is carboxylated by
acetyl-CoA carboxylase (ACC) to malonyl-CoA. ACC is modulated by AMPK activity, phosphorylating
ACC and reducing ACC activity.
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contribution of AGC to the uptake of glutamate in astrocytic mitochondria, as it has been shown
to be primarily expressed in neurons. However, while the AGC activity in astrocytes corresponds
only to 7% of the total brain AGC activity, it is calculated to be twice the minimum required for
glutamate production and degradation (Figure 3.2.6) (Hertz, 2011). AGC is also central to the
malate-aspartate shuttle (Figure 3.1.6), a system that allows the transfer of NADH electrons
generated in the cytosol, from processes such as glycolysis, to the mitochondria (Amoedo et al.,
2016). On the other hand, knockdown of GC1 suggests that this carrier is the main gate for net
glutamate entry into mitochondria for oxidative metabolism in astrocytes (Figure 3.2.6) (Goubert
et al., 2017). In the mitochondria, glutamate is metabolized to KG by transamination via
aspartate aminotransferase (GOT2), and to a lesser extent by alanine (ALAT) and branched chain
aminotransferases (BCAT) (Figure 3.2.4). In addition, -KG can also be synthesized from
glutamate via glutamate dehydrogenase (GDH), which is also a source of NADPH. While
glutamate transamination via GOT2 generates a truncated TCA cycle due to the requirement of
oxaloacetate as a co-substrate, GDH-mediated dehydrogenation can serve as an anaplerotic
reaction to replenish TCA intermediates (Figure 3.2.1 and 3.2.4) (Sonnewald et al., 1993;Olsen
and Sonnewald, 2015;McKenna et al., 2016). Astrocytes deficient in GDH increase their reliance
on GOT2 and their glycolytic input to PC, which is paralleled by an accumulation of intracellular
glutamate, underlying the importance of GDH in anaplerosis (Nissen et al., 2015;Pajecka et al.,
2015). It should be noted that humans, unlike most other animals including mice and rats, have an
additional GDH2 isoform that is expressed solely in astrocytes. Expression of GDH2 in rat
cortical astrocytes increased glutamate uptake and metabolism, reducing their dependence on
glucose and increasing their capacity to utilize branched chain amino acids (BCAA) (Nissen et
al., 2017). Importantly, glutamate to glutamine metabolism is not determined by the extracellular
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glutamate concentration. However, the entry of glutamate into the TCA cycle seems to be
triggered by high extracellular glutamate concentrations (high µM) (McKenna et al., 1996).
The homeostasis of the inhibitory neurotransmitter -aminobutyric acid (GABA) is
similarly linked to the glutamate-glutamine cycle. GABA is synthesized in neurons from the
decarboxylation of glutamate by glutamate decarboxylase (GAD). After its vesicular release,
GABA is uptaken by astrocytes through the GABA transporter (GAT3) (Figure 3.3.4). GABA is
then metabolized by GABA transaminase (GABA-T) with α-KG as cofactor to produce succinate
semialdehyde (SSA) and glutamate (Figure 3.2.4). SSA is metabolized to succinate via SSAdehydrogenase (SSADH), which can then be incorporated back into the TCA cycle. This
anaplerotic addition of succinate compensates the cataplerotic loss of carbons from the generation
of glutamate by the GABA-T (Figure 3.2.1) (Schousboe et al., 2013).

In addition to metabolism, evidence indicates that astrocyte mitochondrial bioenergetics
are important for the regulation of neurotransmitter balance. Both glutamate and GABA uptake
systems in astrocytes are driven by Na+ gradients that are established by the electrogenic action of
the sodium-potassium adenosine triphosphatase (Na+/K+ ATPase) (Figure 3.3.4). PC and GS
activities also require ATP as well, and are critical enzymes in replenishing neuronal
glutamine/glutamate (Figure 3.2.1 and 3.3.4). Importantly, it has been demonstrated that
mitochondria co-localize with EAAT1/2 on the plasma membrane of astrocytes as well as with
glycolysis enzymes (Genda et al., 2011;Bauer et al., 2012) and glutamate transporters physically
interact with the Na+/K+ ATPase (Figure 3.3.6) (Rose et al., 2009), suggesting that while
mitochondrial-derived ATP is not required for astrocyte survival (Supplie et al., 2017), functional
mitochondrial metabolism is important for neurotransmitter uptake and homeostasis (Figure
3.3.2, 3.3.4 and 3.3.6). In fact, astrocyte processes enveloping synaptic terminals contain
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abundant mitochondria (Jackson et al., 2014;Stephen et al., 2015;Jackson and Robinson, 2018),
and inhibition of mitochondrial function by fluorocitrate in astrocytes increases glutamate
excitotoxicity in co-cultures with neurons (Voloboueva et al., 2007).

3.6 Mitochondrial Metabolism in Astrocytes and Redox balance

Astrocytes have less efficient mitochondrial respiration and increased ROS formation
when compared to neurons, in part due to a lower incorporation of complex I into
supercomplexes in astrocytes caused by lower expression of the NADH-ubiquinone
oxidoreductase core subunit S1 (NDUFS1) (Lopez-Fabuel et al., 2016). Regardless, scientific
literature indicates that neurons have limited defense mechanisms against ROS compared to
astrocytes. While both neurons and astrocytes can synthesize GSH, astrocytes have been reported
to protect neurons via regulation of GSH metabolism (Chen et al., 2001;Shih et al., 2003). This
protective effect is thought to be dependent on the supply of cysteine from astrocytes as a
precursor for de novo GSH synthesis (Dringen et al., 1999;Wang and Cynader, 2000), and in part
due to neurons being unable to uptake significant extracellular cystine (Sagara et al.,
1993;Kranich et al., 1996). GSH has been proposed to be released from astrocytes via the ATPbinding cassette transporters subfamily C member 1 transporter (ABCC1, or multidrugresistance-associated protein 1 [MRP1]) (Figure 3.1.6 and 3.3.2) (Hirrlinger et al.,
2002;Hirrlinger and Dringen, 2005). Indeed, inhibition of MRP1 has been reported to reduce the
extracellular accumulation of GSH in cultured astrocytes (Hirrlinger and Dringen, 2005). We
have failed to observe a reciprocal accumulation of GSH in astrocytes when MRP1 activity is
reduced (unpublished data), but this effect might be ascribed to feedback inhibition of GSH
synthesis by GSH.
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Once released, GSH is degraded by the γ-glutamyl transpeptidase (γGT) to produce lcysteine-l-glycine (CysGly) (Dringen et al., 1997). CysGly is cleaved further by the neuronal
aminopeptidase N (ApN) into the amino acids glycine and cysteine that are taken up by neurons
for de novo GSH synthesis via GlyT1 and EAAT3, respectively (Figure 3.3.2 and 3.3.3)
(Dringen et al., 1999;Dringen et al., 2001;Aoyama et al., 2008;Belanger et al., 2011). The export
of GSH should imply a loss of carbons that must be replenished in astrocytes to maintain
cellular redox homeostasis. Cysteine acquisition in astrocytes is mediated by Na +-dependent
and -independent uptake systems, but the exact contribution of X AG-/EAAT3 and X c-/xCT
systems is still under debate (Shanker et al., 2001;Seib et al., 2011). De novo synthesis via the
trans-sulfuration (TSP) pathway is also an important source for cysteine in astrocytes, and was
shown to be upregulated and utilized during oxidative stress (Figure 3.3.2) (Vitvitsky et al.,
2006). In most cells, cysteine is considered the limiting substrate for GSH synthesis. However,
because glutamate in astrocytes is also metabolized to glutamine, it might also be considered a
limiting factor (Figure 3.1.6). Because glutamate synthesis depends on mitochondrial
anaplerotic metabolism, mitochondrial function might also be essential for GSH homeostasis
(Figure 3.2.1 and 3.2.4). Interestingly, GSH depletion upregulates mitochondrial activity and
expression of complex I in astrocytes (Vasquez et al., 2001), but the exact mechanisms that
regulate this phenomenon are still unclear.

3.7 Conclusions and perspectives

The scientific process has been aptly described as blind people attempting to describe an
elephant while only focusing on particular parts of the animal. Each person is contextually
correct, but only when the data is combined can we achieve an accurate understanding of the
whole. While there are far more parts of the proverbial elephant to explore to complete the
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picture, the recent evidence indicates that we must adjust our current understanding of brain
metabolism, particularly as it pertains to astrocytes and neurons.

Current research indicates that metabolism in the brain extends far beyond glucose. Fatty
acids, and their derived ketone bodies, are important sources of bioenergetic potential for the
brain, particularly during development, as shown by the experiments in vivo and in vitro that
follow its oxidation and integration into biomolecules. Glutamate is more than just a
neurotransmitter kept in strict stoichiometry by the glutamate-glutamine cycle; it is a resource the
brain uses for amino acid synthesis by transamination, for redox balance by generation of
NADPH, and for anaplerosis to maintain the TCA cycle.

The brain is far from a homogeneous body of cells, and the literature paints a clear
picture of metabolic specialization and intracellular cooperation/dependence. In this chapter, we
have centered our attention to astrocytic mitochondrial metabolism and its role in the regulation
of brain bioenergetics, neurotransmission and redox balance via neuronal-astrocyte metabolic
interactions. Astrocytes have been demonstrated to be functional without OXPHOS in vivo, to
provide a GSH-dependent protective effect to neurons, to function as neutralizing and cycling
agents of glutamatergic/GABAergic signaling, and to be synthesizers/exporters of OXPHOS
bioenergetic molecules (lactate/ketone bodies). In contrast, neurons have a metabolic
specialization towards OXPHOS, spurning FAO, restricting glucose oxidation while maintaining
the PPP for redox homeostasis, and limiting their ability to conduct mitochondrial biosynthesis
due to a lack of pyruvate carboxylase for anaplerosis. Together, neurons shoulder the bioenergetic
burden of neurotransmission by controlled alterations in cell potential, while astrocytes conduct
biosynthesis and high ROS oxidative processes to supplement neuronal functions.
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The key organelle in this differential specialization is the mitochondria. While the broad
mitochondrial role in OXPHOS is well known in mammalian cells, specialization is evident
within neurons and astrocytes. Astrocytes restrict the conversion of pyruvate to acetyl-CoA by
their phosphorylation of PDH, limiting their utilization of glucose for OXPHOS but instead
directing these carbons to biosynthesis through the TCA cycle by PC. Additionally, the efficiency
of the astrocyte ETC is far less than neurons, resulting in higher ROS generation in astrocyte
compared to neurons. Astrocytic mitochondria have been demonstrated to utilize FAO for the
production of ketone bodies, a process that has not been shown to be significant in neurons.
Further, evidence shows that astrocytes localize mitochondria to endfeet processes in conjunction
with glutamate transporters and enzymes related to glycolysis. Coupled with the evidence that
OXPHOS is not required in astrocytes in vivo, this paints a unique picture for astrocyte
mitochondria compared to the prototypical mammalian cell. It is a mitochondria specializing in
synthesis at the expense of OXPHOS, while the neuronal mitochondria specialize in OXPHOS at
the expense of synthesis.
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3.8 List of Abbreviations

2-HPCL

2-hydroxyphytanoyl-CoA lyase

3-OHacyl-CoA

3-hydroxyacyl-Coenzyme A

ABCC1/MRP1

adenosine-triphosphate-binding cassette transporter subfamily C member 1 or
multidrug-resistance-associated protein 1

ABCD1

adenosine triphosphate binding cassette subfamily D member 1

AcAc

Acetoacetate

ACAT

acetyl-CoA C-acetyltransferase, acetoacetyl-CoA thiolase II

ACC

acetyl-CoA carboxylase

ACD

acyl-CoA dehydrogenase

ACS

acyl-CoA synthetase

AGC

aspartate/glutamate carrier antiporter or Aralar 1

G

-ketoglutarate

ALAT

alanine aminotransferase

ALDP

adrenoleukodystrophy protein

AMPK

adenosine monophosphate activated protein kinase

ANLS

astrocyte-neuron lactate shuttle

ANT

adenine nucleotide transporter

ApN

aminopeptidase N

ApoE/D

apolipoprotein E/D

ATP

adenosine triphosphate

BBB

blood-brain barrier

BCAA

branched chain amino acids

BCAT

branched chain aminotransferases

BDH

β-hydroxybutyrate dehydrogenase

CACT

carnitine/acylcarnitine translocase

cAMP

cyclic adenosine monophosphate

CAT

catalase
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CIC

citrate isocitrate carrier

CNS

central nervous system

CNTF

ciliary neurotrophic factor

CoA

coenzyme A

CPT

Carnitine palmitoyltransferase

CysGly

l-cysteine-l-glycine (CysGly)

EAAT

excitatory amino acid transporter

ECH

enoyl-CoA hydratase

ETC

electron transport chain

ETF

electron transferring flavoprotein

F2,6BP

fructose-2,6-bisphosphate

FA

fatty acid

FADH2

flavin adenine dinucleotide

FAO

fatty acid oxidation

FAT/CD36

fatty acid translocase

FATP

fatty acid transport protein

GABA

γ-aminobutyric acid

GABA-T

γ-aminobutyric acid transaminase

GAD

glutamate decarboxylase

GAT

γ-aminobutyric acid transporter

GC1

glutamate carrier or SLC25A22

GDH

glutamate dehydrogenase

GFAP

glial fibrillary acidic protein

GLAST

glutamate aspartate transporter or excitatory amino acid transporter 1

GLT-1

glutamate transporter 1 or excitatory amino acid transporter 2

GOT1

cytosolic aspartate aminotransferase

GOT2

mitochondrial aspartate aminotransferase

GS

glutamine synthetase
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GSH

glutathione

HAD

3-hydroxyacyl-Coenzyme A dehydrogenase

HMCS1

β-hydroxy-β-methyl glutaryl (HMG)-CoA synthase

HMGCL

HMG-CoA lyase

IP3

inositol triphosphate,

LCFA

long chain fatty acid

MCFA

medium chain fatty acids

MCT

monocarboxylate transporter

MPC

mitochondrial pyruvate carrier

Na+/K+ ATPase

sodium-potassium adenosine triphosphatase

NADH

nicotinamide adenine dinucleotide

NADPH

nicotinamide adenine dinucleotide phosphate

NDUFS1

nicotinamide adenine dinucleotide ubiquinone oxidoreductase core subunit S1

OXPHOS

oxidative phosphorylation

PAG

phosphate-activated glutaminase

PC

Pyruvate carboxylase

PDH

pyruvate dehydrogenase

PEP

phosphoenolpyruvate

PEPCK

phosphoenolpyruvate carboxykinase

PFK1

phosphofructokinase 1

PFKFB3

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3

PhyH/Pahx

phytanoyl-CoA hydroxylase

PPAR

peroxisome proliferation activated receptor

PPP

pentose phosphate pathway

PUFA

poly-unsaturated fatty acid

Redox

reduction-oxidation

RET

reverse electron transfer

ROS

reactive oxygen specie
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SCFA

short chain fatty acids

SCOT

succinyl‐CoA‐3-oxoacid-CoA transferase

SNAT

sodium-coupled neutral amino acid transporter

SSA

succinate semialdehyde

SSADH

succinate semialdehyde dehydrogenase

TCA cycle

tricarboxylic acid or Krebs cycle

TSP

transsulfuration pathway

VDAC

voltage-dependent anion channel

VLCFA

very long chain fatty acid

XAG-/EAAT3

aspartate-glutamate transporter

βHB

β-hydroxybutyrate

γGT

γ-glutamyl transpeptidase

Xc-/xCT

cystine-glutamate exchanger
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CHAPTER 4
ASTROCYTES DEPEND UPON MITOCHONDRIA DURING ARSENIC EXPOSURE

4.1 Introduction
As discussed in chapters 2 and 3, astrocytes and neurons perform specialized metabolic
functions for synaptic transmission, with astrocytes primarily maintaining homeostasis. Astrocyte
processes envelope the capillary blood brain barrier (BBB) (Mathiisen et al., 2010), and become
the first central nervous system (CNS) cells to encounter toxic compounds entering the brain.
While numerous studies have documented the effects of xenobiotics on neuronal function, far
fewer have delved into the effects of xenobiotics on astrocytes. While astrocytes have
demonstrated resilience in the face of xenobiotic challenges compared to other CNS cell types
(Hollensworth et al., 2000;Rathinam et al., 2012), how astrocyte metabolism changes to
compensate for xenobiotic exposure has not been fully explored. In particular, the role of
mitochondrial metabolism in astrocytes has often been overlooked, in part because of the
aforementioned resilience of astrocytes to xenobiotic challenges and the demonstrated glycolytic
nature of astrocytes (Supplie et al., 2017). Given the interconnected nature of astrocyte-neuron
metabolism, it is imperative to understand what metabolic alterations are induced in astrocytes by
xenobiotics to understand how xenobiotic toxicity affects neurotransmission.
Arsenic is a metalloid element with a widespread, variable distribution throughout the
Earth’s crust. The high aqueous solubility of inorganic arsenicals allows for high groundwater
contamination (Nordstrom, 2002;Duker et al., 2005). One of the best documented exposure to
arsenic contaminated water occurred in the 1980s in Bangladesh, when shallow wells were
constructed to increase access to clean water. The issue went largely unaddressed until 1998, and
water analysis revealed that 34.9% of the 19,845 wells of the flood plains had arsenic
contamination above the World Health Organization’s (WHO) maximum permissible limit of 50
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µg/L, with the highest measured concentration being 4730 µg/L (Chakraborti et al., 2015). No
level of arsenic contamination is without risk, as illustrated in a study of verbal, intellect quotient,
and long term memory on Bangladeshi children found that the inverse correlation between each
test and arsenic water contamination could be observed even between 0.1-5.5ug/L and 5.6-50ug/L
groups (Wasserman et al., 2004). Further, arsenic associated skin lesions have been reported
following chronic exposure to water containing less than 10ug/L of arsenic (Ahsan et al.,
2000;Ahsan et al., 2006), however the link to skin cancer at these concentrations is still debated
(see (Hong et al., 2014) for a review on chronic arsenic exposure symptoms). The arsenic
contaminated water was also used in irrigation, and an ensuing analysis of regions with high
arsenic contamination (200-500 µg/L) found a mean arsenic accumulation of 358 µg/kg and 333
µg/kg in rice and vegetables, respectively. Further, 87% of the arsenic in rice and 96% of the
arsenic in vegetables were in inorganic forms (Smith et al., 2006). Arsenicals, such as p-arsanilic
acid and nitarsone, that are not readily absorbed into animals are used in animal feed to mitigate
protozoan infections and are excreted. However, when manure from these animals is used as
fertilizer, the arsenicals are absorbed into agricultural products such as rice. The plants then
convert the arsenicals into forms that are readily absorbed and toxic to animals, such as arsenite
(AsIII), monomethylarsonic acid (MMA), dimethylarsinic acid (DMA), and arsenate (AsV) (Geng
et al., 2017).
Inorganic arsenic typically exists in two oxidation states, the pentavalent arsenate (AsV)
that predominates in oxygenated or oxidizing environments, and the trivalent arsenite (AsIII) that
predominates in reductive environments (Duker et al., 2005). Arsenite enters the cell through
aquaglycoporins (Liu et al., 2004) and glucose transporters (Liu et al., 2006), while arsenate
enters through phosphate transporters (Villa-Bellosta and Sorribas, 2010). Early studies on
mammalian arsenic exposure revealed that DMA and MMA in the pentavalent form (DMAV and
MMAV) were present in urine. DMAV and MMAV displayed reduced cytotoxicity, but were later
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found to possess carcinogenic properties. It was later discovered that the trivalent forms of the
metabolites (DMAIII and MMAIII) were also present in urine and were more carcinogenic than the
pentavalent forms (reviewed in (Drobna et al., 2009)). Further, the principal enzyme in
methylation of inorganic arsenic in humans, arsenic methyltransferase (AS3MT), uses trivalent
arsenicals as a substrate. Further, methylation is promoted in the presence of GSH and reductases
(Waters et al., 2004), reinforcing the proposed model whereby arsenicals alternate their oxidation
state during methylation (Challenger, 1947). Further supporting this notion is the observed
preference for glutathionylated arsenicals by AS3MT (Hayakawa et al., 2005), and the discovery
of glutathionylated arsenicals in the urine of mice deficient in ɣ-glutamyltranspeptidase
(ɣGT)(Kala et al., 2004).
In the brain, AS3MT has been shown to be highly expressed in astrocytes compared to
neurons (Li et al., 2016), but it has also been reported that cultured astrocytes do not produce
significant quantities of methylated arsenic species (Koehler et al., 2014). Nevertheless, the
literature also indicates that methylated arsenic is produced in brain slices exposed to arsenic
(Rodriguez et al., 2005), and that astrocytes are highly resistant to the effects of methylated
arsenicals (Jin et al., 2004;Meyer et al., 2013). This methylation vs. glutathionylation distinction
is important, as a methylation process with a glutathionylated arsenical intermediate would be
expected to release GSH, or a derivative of GSH, back into the intra- or extracellular
compartments. Further, triglutathionylated arsenical has been proposed to be exported by MRP1
(Leslie et al., 2004). However, this experiment was performed in HeLa cells and MRP1 has
altered substrate specificity and kinetics depending on cell type (Banerjee et al., 2018), and
corresponding post-translational modifications (Shukalek et al., 2016).
The importance of determining the mechanism of arsenic toxicity in the cells of the CNS
is underscored by the neurodegenerative and cognitive impairment observed with chronic arsenic
exposure. Multiple inverse correlations have been found between intelligence quotient (IQ)
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parameters and environmental arsenic exposure during childhood (Rosado et al., 2007;Dong and
Su, 2009;Hamadani et al., 2011;Wasserman et al., 2014). How this occurs has not been
determined, though there is evidence that arsenic exposure alters neurotransmitter homeostasis
(Yadav et al., 2010;Jiang et al., 2014;Ramos-Chavez et al., 2015), long term potentiation (Kruger
et al., 2009), and mitochondrial function (Hu et al., 1998;Prakash et al., 2015). Arsenic has also
been proposed to induce the production of reactive oxygen species (ROS) in the brain,
particularly in neurons (Piao et al., 2005;Dwivedi and Flora, 2011;Flora, 2011;Prakash and
Kumar, 2016), as well as alter the expression of excitatory amino acid transporters (CastroCoronel et al., 2011;Zhao et al., 2012).
The effects of arsenic induced mitochondrial dysfunction have been difficult to elucidate.
Isolated rat liver mitochondria have been shown to reduce arsenate to arsenite in a manner that is
dependent upon electron transport chain activity (Nemeti and Gregus, 2002). Further, arsenite,
and to a lesser extent methylated arsenite species, have been shown to inhibit both purified
pyruvate dehydrogenase

activity by binding to the reduced lipoic acid moieties

(Bergquist et al., 2009). In line with this observation, arsenite exposure has been shown to reduce
mitochondrial complex activities and oxygen consumption, while increasing the mutation rate of
nuclear and mitochondrial DNA in a manner dependent upon mitochondrial activity (Liu et al.,
2005;Partridge et al., 2007;Hosseini et al., 2013). The DNA damage does not appear to be a direct
effect of arsenic on DNA repair enzymes (Hu et al., 1998). Instead, DNA damage may be indirect
effect of the ROS generated from arsenic exposure (Ramanathan et al., 2003;Hosseini et al.,
2013;Prakash et al., 2015). However, ROS may not be directly produced by arsenic, and it has
been proposed that GSH depletion during arsenite exposure is the source of the observed ROS
(Han et al., 2008).
In this chapter, arsenic was used as a representative xenobiotic to explore alterations to
astrocyte metabolism during xenobiotic exposure. The experiments confirm previous reports that
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astrocyte arsenic detoxification is glutathione (GSH) and multi-drug resistance associated protein
1 (MRP1) dependent, and that astrocytes remain viable when challenged with mitochondrial
toxins. The experiments highlight that astrocyte viability is compromised during arsenic exposure
by the loss of mitochondrial functions, inhibition of mitochondrial carbon inputs from pyruvate
and fatty acids, and loss of aminotransferase activity. Further, arsenic exposure causes astrocytes
to efflux glutamate to the media, generating extracellular glutamate concentrations that would be
considered excitotoxic to neurons.

4.2 Materials and Methods
4.2.1 Cell Culture
Primary cortical astrocytes from post-natal day 1-2 C57Bl/6 mice were obtained from
stocks previously frozen by Dr Annadurai Anandhan and Dr Carla Garza-Lombo, following the
protocol of (Waagepetersen et al., 2002). Astrocytes were cultured in Dulbecco's Modified Eagle
Medium with nutrient mixture F-12 (DMEM:f12, Hyclone) supplemented with 10% fetal bovine
serum (FBS, Atlanta Biologicals), and 200 U/ml penicillin + 200 μg/ml streptomycin (P/S,
Lonza). Cultured astrocytes were kept at 37°C in 5% carbon dioxide (CO2) humidified incubator.
Astrocytes were used up to the third passage.

4.2.2 Flow Cytometry
Astrocytes were seeded into 12-well plates at a density of 84,000 cells/ml. Fresh media
supplemented with treatments was provided once the astrocytes reached 95% confluency. Cells
were treated for 48hrs under the conditions above. Cell viability was determined with propidium
iodide uptake (PI, 1 μg/ml) (Life Technologies) detecting loss of plasma membrane, and
monochlorobimane (mBCl, 10 μM) (Molecular Probes) measuring intracellular GSH content.
Flow cytometry was performed as described previously (Anandhan et al., 2017).
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4.2.3 ICP-MS
Astrocytes were seeded into 12-well plates at a density of 84,000 cells/ml in DMEM:f12
supplemented medium as described above. Fresh DMEM:f12 supplemented with treatments was
provided once the astrocytes reached 95% confluency. At the indicated time points, the media
was removed and the cell trypsinized. Twice, the cells were pelleted, the supernatant removed,
and the pellet gently resuspended in phosphate buffered saline (PBS). Half of each sample was
then sent for ICP-MS, while the other half was used for normalization by a Pierce bicinchoninic
acid (BCA) protein assay (Thermo). ICP-MS was performed as per (Anandhan et al., 2015).

4.2.4 Glutamate Quantification
Astrocytes were seeded into 12-well plates at a density of 84,000 cells/ml in DMEM:f12
supplemented medium as described above. Once the astrocytes reached 95% confluency, the cells
were washed with prewarmed PBS and given Neurobasal A media supplemented with 1% B27,
2.5 mM glutamine and treatments for 24 hrs. The Neurobasal A media was removed and the
sample was centrifuged at 300 g for 5 mins to pellet and remove any loose cells. Neurobasal
media was then used in a Glutamate-Glo kit (Promega) as per manufacturer’s instructions for 50
µl of samples. Media samples were diluted fourfold in PBS to keep measurements within the
linear range of the kit. Results were normalized to total media volume at the time of collection,
and to total protein content of the cells by a Pierce bicinchoninic acid (BCA) protein assay
(Thermo).

4.2.5 ATP Quantification
Astrocytes were seeded into 96-well plates at a density of 7000 cells/well in DMEM:f12
supplemented medium as described above. Fresh DMEM:f12 supplemented with treatments was
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provided once the astrocytes reached 95% confluency. After 24 hrs of treatment, Cell-Titer Assay
(Promega) was performed as per manufacturer’s instructions to quantify the total ATP content of
each well.

4.2.6 Seahorse Mitochondrial Oxygen Consumption
Oxygen consumption (OCR, pmol/min) was determined using XFe24 Analyzer (Seahorse
Biosciences) as per (Anandhan et al., 2017) with modifications outlined below. Astrocytes were
grown to confluency in DMEM:f12 supplemented media as previously described and before
additional media containing treatment factors was added. Treatment occurred in a CO2-less
incubator at 37°C for 24 hrs. After treatment, cells were washed and incubated for 1hr in HCO3
and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) free DMEM (Gibco)
supplemented with 2.5 mM glutamine, 17.5mM glucose, 1mM pyruvate and treatment factors
prior to OCR measurements. OCR measurements were conducted using a final concentration of
1µM oligomycin, 1µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP), and a mixture of
0.5 µM rotenone and 0.5 µM antimycin A. Measurements were normalized to total protein
concentration. OCR was used as an indicator of mitochondrial function and capacity, as described
by the manufacturer’s protocols.

4.2.7 NMR Metabolomics
Astrocytes were seeded onto 100 mm dishes at a density of 1.2x106 cells/9ml. Upon
reaching 95% confluency, cells were washed twice with 1 ml prewarmed PBS. DMEM media
supplemented with 17.5 mM U-13C glucose, 1 mM pyruvate, and 2.5 mM glutamine in addition to
10% FBS and P/S, and sodium arsenite. For glutamate metabolomics, 17.5 mM unlabeled
dextrose was used, and 100 µM U-13C/15N glutamate was added. Following 24 hrs, cells and
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media were collected by Jade Woods and Alexandra Crook, with 2D 1H-13C NMR HSQC
experiments were performed as per (Bhinderwala et al., 2019).

4.3 Results
4.3.1 Arsenic Exposure Creates a Reduced Intracellular State
Previous reports have implicated the glutathionylation of arsenicals in the detoxification
process of many mammalian cell types, including astrocytes, that is either directly excreted or
converted to a methylated arsenical for export (Cui et al., 2004;Leslie et al., 2004;Hayakawa et
al., 2005). Flow cytometry was used to measure intracellular GSH and membrane integrity of
astrocytes with various arsenic concentrations. In this regards, the results were used to determine
if the loss of GSH was a measurable characteristic of arsenic toxicity by flow cytometry. Viable
cells were defined as cells that are mBCl positive and PI negative. Preliminary data from
Anandhan Annadurai showed that GSH depletion proceeded loss of membrane integrity (Figure
4.1A). In line with previous reports, low concentrations of arsenic increased the intracellular GSH
concentration compared to the non-treated controls (Figure 4.1B).

4.3.2 Arsenic Exposure Increases Glutamate Synthesis from Glucose
Nuclear magnetic resonance (NMR) was used to create a metabolomic profile of
astrocytes cultured with U-13C-glucose at the previously utilized arsenic concentrations by
Anandhan Annadurai and Shulei Lei. As shown in Figure 4.2A, the intracellular compartment
demonstrated a significant fold increase in 3-phosphoglycerate (a precursor to both glycine and
cysteine synthesis) during arsenic exposure. Conversely, the concentration of fructose-6phosphate first decreased at low arsenic concentrations and then increased at higher arsenic
concentrations. Notably, intracellular lactate remained initially constant and only decreased at the
highest arsenic concentrations, while UDP-glucose decreased at all tested arsenic concentrations.
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Figure 4.1: Intracellular REDOX state of Astrocytes exposed to Arsenic
(A) Flow cytometry performed on astrocytes following 48hrs of the indicated arsenic treatment. (B)
Quantification of the fold change in mBCl signal in the dashed boxes of (A). *: p<.05 by student T-test.
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While cysteine was not sufficiently labeled from U-13C-glucose to detect by NMR, and glycine
remained relatively constant, intracellular glutamate concentrations did decrease significantly at
higher arsenic concentrations.
Additionally, the culture media was analyzed for the presence of 13C-labeled products. As
shown in Figure 4.2B, the efflux of both 13C-labeled lactate and citrate significantly increased at
low levels of arsenic exposure, while being reduced at high arsenic concentrations. Unexpectedly,
the extracellular concentration of labeled glutamate, not glutamine, dramatically increased during
arsenic exposure. This contrasts with the intracellular data, but indicates that glucose carbons may
be shuttled to glutamate production and exported by some undetermined process.

4.3.3 Astrocyte Viability is Limited by GSH Synthesis, not GSH Recycling, during Arsenic
Exposure
Due to ROS being a hallmark of arsenic exposure, and the incompletely defined role of
GSH in arsenic detoxification, it was important to address whether the survival limiting aspect is
GSH de novo synthesis or REDOX cycling of an existing GSH pool. If GSH is being used
principally in a consumptive process during arsenic exposure, such as in forming a stable
complex with arsenic and being excreted, inhibition of de novo GSH synthesis by buthionine
sulphoximine (BSO) would greatly sensitize astrocytes to arsenic. However if GSH was instead
being principally used as a reducing agent for arsenic derived ROS, then inhibition of the pentose
phosphate pathway (PPP) by 6-aminonicotinamide (6-AN) would be expected to sensitize
astrocytes to arsenic by limiting the ability to reduce oxidized glutathione (GSSG) to GSH
(Figure 4.3C). While 6-AN had no significant effect on cell viability (Figure 4.3A), BSO
dramatically sensitized the astrocytes to arsenic while having minor effects on viability when
administered alone (Figure 4.3B). Both compounds were also tested against hydrogen peroxide
treatment, demonstrating that each compound reduced cell viability in the presence of reactive
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Figure 4.2: 2D-NMR Metabolomics with U-13C-glucose
2D-NMR (1H-13C) metabolomics performed on astrocytes treated with the indicated arsenic concentrations
in media containing 17.5mM U-13C-glucose for 24hrs. Cellular (A) and media (B) components were
measured for each sample and represented as fold change compared to control. (C) Pathway model of the
results from (A-B). *: p<.05 by One Way ANOVA compared to untreated control.
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Figure 4.3: Inhibition of GSH synthesis and REDOX cycling during Arsenite Exposure
(A-B) Viable cell population determined by flow cytometry following 48hrs of sodium arsenite or
hydrogen peroxide, vs. 1mM 6-AN (A) or .5mM BSO (B). (C) Graphical representation of GSH pathways
and the inhibitors used. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) or the control at the
same arsenic/peroxide concentration (b).
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oxygen species (ROS) (Figure 4.3A-B). These results provide evidence that arsenic
detoxification involves a process that consumes GSH, and implies that glutathionylation of
arsenic and/or GSH efflux is a significant effect in astrocytes during arsenic exposure.

4.3.4 Astrocyte Arsenic Detoxification is Dependent upon MRP1
The accumulation of intracellular arsenic within astrocytes was determined in order to
approximate a tipping point for detoxification. Utilizing inductively coupled plasma mass
spectrometry (ICP-MS) a time course of intracellular arsenic accumulation in astrocytes was
established for 5, 10, and 20 µM sodium arsenite (NaAsO2) exposure over a 24hr period. 10 µM
sodium arsenite (NaAsO2) established an approximate equilibrium between efflux and influx
(Figure 4.4A), while 5 µM sodium arsenite did not show significant arsenic accumulation beyond
the 6hr time point. As MRP1 has been previously implicated in the efflux of glutathionylated
arsenicals (Leslie et al., 2004), astrocyte viability and intracellular arsenic accumulation was
measured in the presence of an MRP1 inhibitor (MK571). In contrast with previous results
(Tadepalle et al., 2014), MK571 sensitized astrocytes to arsenite (Figure 4.4B), though the
increase in intracellular arsenic accumulation (Figure 4.4C) is consistent with that study. MK571
was not found to have an effect on viability during peroxide treatment (Appendix Figure 1),
reinforcing that MRP1 activity during arsenic exposure is not directly related to ROS production.

4.3.5 Extracellular Glutamate Accumulates in Astrocyte Cultures Exposed to Arsenic
To corroborate the glutamate efflux in the NMR results, an enzymatic assay (GlutamateGlo, Promega) was performed to quantify the total glutamate in the astrocyte culture media. As
the assay measures total glutamate, and not just glutamate produced by astrocytes, Neurobasal A
media rather than DMEM was used following astrocyte confluency, as the DMEM media
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Figure 4.4: ICP-MS Time Course of Intracellular Arsenic and MRP1 Inhibition
(A) Intracellular arsenic accumulation time course by ICP-MS at the indicated arsenic exposures. α,ß,ɣ:
p<.05 by Two Way ANOVA within a time point between: 20µM vs. 10µM (α), 20µM vs. 5µM (ß), and
10µM vs. 5µM (ɣ). *: p<.05 by Two Way ANOVA between untreated cells and treated cells. (B) Viable
cell population determined by flow cytometry following 48hrs of sodium arsenite vs. 25µM MK571. (C)
Intracellular arsenic accumulation by ICP-MS after 24hrs at the indicated arsenic exposures vs. 25µM
MK571. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) or the control at the same arsenic
concentration (b).
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contained approximately 50 µM glutamate. As in the NMR experiment, the presence of arsenic
dramatically increased the quantity of glutamate produced by astrocytes (Figure 4.5A).

4.3.6 Extracellular Glutamate Accumulation is not dependent on MRP1 or ɣGT
As described in chapter 2, astrocytes produce GSH for neurons, which is broken down by
astrocyte ɣ-glutamyltranspeptidase (ɣGT) and neuronal aminopeptidase N (ApN) into its amino
acid components. Additionally, this astrocyte GSH export process and arsenic detoxification are
both dependent upon MRP1 (Figure 4.4B-C). Enzymatic quantification of extracellular
glutamate from astrocytes given ɣGT (Acivicin) or MRP1 (MK571) inhibitors was used to
determine if the decomposition of arsenic-GSH complexes or GSH were the sources of the
extracellular glutamate, but no significant differences were observed (Figure 4.5A).

4.3.7 Extracellular Glutamate Accumulates Independently of Arsenic during EAAT1/2
Inhibition, but only EAAT1 sensitizes Astrocytes to Arsenic
As excitatory amino acid transporters have been reported to reverse transport under
certain conditions, inhibitors UCPH-101 (EAAT1) and WAY-213613 (EAAT2) were applied to
astrocytes with or without arsenic, and found that significant glutamate accumulated outside of
the cell independent of arsenic exposure. (Figure 4.5A). Given that intracellular glutamate
decreased in the presence of arsenic (Figure 4.2A) and that EAAT1/2 inhibition increased
extracellular glutamate accumulation (Figure 4.5A), it was important to determine if the function
of EAAT1 and EAAT2 would sensitize astrocytes to arsenic. Administration of both UCPH-101
and WAY-213613 caused a significant decrease in viability in the presence of arsenic (Figure
4.5B). To test if this was a synergistic effect of both compounds or if one transporter was
primarily responsible, the test was repeated with each inhibitor assayed independently, and
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Figure 4.5: Extracellular Glutamate and Arsenic Sensitivity Impacted by EAAT Inhibition
(A) Extracellular glutamate concentration measured by Glutamate-Glo following arsenic treatment vs.
100µM acivicin, 25µM MK571, or a mixture of 10µM UCPH-101 and 10µM WAY213613. (B-D) Viable
cell population determined by flow cytometry following 48hrs of sodium arsenite vs. (B) a mixture of
10µM UCPH-101 and 10µM WAY213613, (C) 10µM UCPH-101, (C) 10µM WAY213613, or (D) 50µM
SAS. *: p<.05 by Two Way ANOVA compared to the control at the same arsenic concentration. a,b: p<.05
Two Way ANOVA vs. the untreated control (a) or the control at the same arsenic concentration (b).
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demonstrated that the effect was due to EAAT1, with no significant effect observed with EAAT2
inhibition (Figure 4.5C).

4.3.8 Inhibition of xCT has Minor Sensitizing Effects on Astrocytes to Arsenic
The cystine-glutamate antiporter (xCT) is a means to acquire the limiting component
cysteine for GSH synthesis in astrocytes through glutamate efflux(Cho and Bannai, 1990;Allen et
al., 2001;Allen et al., 2002;Seib et al., 2011). The increased extracellular glutamate accumulation
(Figure 4.5A) and the necessity of GSH synthesis (Figure 4.3B) during arsenic exposure in
astrocytes implies the xCT system may be required to maintain intracellular cysteine
concentrations during arsenic exposure. However, only a small but significant increase in arsenic
sensitivity was observed with the application of sulfasalazine (SAS) during arsenic exposure,
indicating that xCT is not likely a critical factor (Figure 4.5D). Additionally, astrocyte viability
was tested during arsenic exposure in media supplemented with cystine (200µM) or methionine
(200µM), but no protective or sensitizing effect was observed (Appendix Figure 2A)

4.3.9 Inhibition of Mitochondria or Transamination Sensitizes Astrocytes to Arsenic
While the route of glutamate efflux remains to be determined, the observed reduction of
intracellular glucose labeled glutamate during arsenic exposure (Figure 4.2A) coupled with the
arsenic sensitizing effect of EAAT1 inhibition (Figure 4.5D) implies that glutamate could be a
limiting substance for astrocyte survival. Though the most direct route of glutamate procurement
would be the deamination of glutamine through glutaminase, preliminary results have shown that
the application of the glutaminase inhibitor BPTES had no significant effect on cell viability with
and without the presence of arsenic (Suppl. Figure 2B). De novo synthesis of glutamate requires
mitochondrial processes, and astrocytes were therefore challenged with mitotoxins to determine if
mitochondrial inhibition altered arsenic sensitivity. In agreement with previous results (Rathinam
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et al., 2012;Zhang et al., 2015), astrocytes remained viable in the presence of low concentrations
of the mitochondrial toxins rotenone, paraquat (PQ), or 1-methyl-4-phenylpyridinium (MPP+),
but each of these compounds sensitize astrocytes to arsenic (Figure 4.6A). Experiments were
performed to determine whether electron transport chain or carbon input restrictions to the
mitochondria impacted total ATP. ATP levels exhibited small but significant decreases when
arsenic was co-administered with UK5099, etomoxir, or rotenone (Figure 4.6B). Carbon
restriction to the mitochondria similarly sensitized the astrocytes to arsenic, while having no
significant independent effect (Figure 4.6C). Additionally, astrocyte viability was tested in the
presence of aminooxyacetic acid (AOAA), as transamination is a key component of glutamate
synthesis. A similar arsenic sensitization occurred with AOAA (Figure 4.6C). 24hr time point
ICP-MS experiments were then performed to determine if UK5099, etomoxir, or AOAA affected
arsenic accumulation in astrocytes. While each compound increased arsenic accumulation,
surprisingly, no significant effect was observed except for etomoxir (Figure 4.6D). Similarly,
measurements of extracellular glutamate following compound treatments did not yield any
significant changes compared to controls, except for etomoxir (Figure 4.6E).

4.3.10 Etomoxir and Arsenic Co-administration Damages Mitochondrial Respiratory Capacity
Given that the mitochondria is providing a critical function in astrocyte survival during
arsenic exposure (Figure 4.6A) and that etomoxir induces significant effects during arsenic
exposure in total ATP (Figure 4.6B), viability (Figure 4.6C), and intracellular arsenic
accumulation (Figure 4.6D), mitochondrial respiration was measured during arsenic and/or
etomoxir exposure utilizing the Seahorse Mito Stress Test (Agilent). As shown in Figure 6,
arsenic had minimal effects on mitochondrial respiration, with a small yet significant decrease in
maximal respiration. Etomoxir treatment almost completely stopped astrocyte mitochondrial
respiration, but only a small change in maximal respiration was observed. Thus, mitochondrial
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Figure 4.6: Mitochondrial Functions are Essential During Arsenic Exposure
(A) Viable cell population determined by flow cytometry following 48hrs of sodium arsenite vs. 1µM
rotenone, 50µM paraquat, or 2.5mM MPP +. (B) ATP quantified by Cell-Titer Glo with the indicated
arsenic concentrations vs. 200µM etomoxir, 5µM UK5099, or 1µM rotenone.
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(Figure 4.6: Mitochondrial Functions are Essential During Arsenic Exposure continued)
(C-E) Viable cell population determined by flow cytometry (C), intracellular arsenic accumulation by ICPMS (D), and extracellular glutamate accumulation measured by Glutamate-Glo (E) at the indicated arsenic
exposures vs. 200µM etomoxir, 5µM UK5099, or 5mM AOAA. *: p<.05 by Two Way ANOVA compared
to the control at the same arsenic concentration. a,b: p<.05 Two Way ANOVA vs. the untreated control (a)
or the control at the same arsenic concentration (b).
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electron transport machinery is still intact in the presence of etomoxir. However, coadministration of etomoxir with arsenic led to a cessation of mitochondrial respiration and a
dramatic decrease in maximal respiration. The results imply that the electron transport
capabilities of the mitochondria were effectively disabled by the co-treatment of arsenic and
etomoxir.

4.3.11 13C/15N Glutamate NMR Preliminary: Arsenic Doesn’t Alter GSH Incorporation, but
Increases Extracellular Glutamate and Intracellular Glutamine.
Given that glutamate is being synthesized by glucose precursors (Figure 4.2) and
effluxed to the extracellular space (Figure 4.5A and 4.6E), NMR samples were generated using
U-13C/15N glutamate to determine if glutamate metabolism had been altered by the presence of
arsenic. While the final data analysis is still pending, preliminary data indicate that glutamate
carbons are being incorporated into lactate, glutamine, and GSH. However, the changes observed
with arsenic treatment were an increase in extracellular glutamate and intracellular glutamine,
with no observed changes in extracellular lactate or intracellular GSH. (Appendix Figure 3).
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Figure 4.7: Mito Stress Test during Arsenic and Etomoxir Exposure
Seahorse Mito Stress Test performed in an XFe24 Analyzer. Astrocytes were treated with/without 200µM
etomoxir and/or 10µM arsenite for 24hrs. Final well concentrations of applied inhibitors are 1µM
oligomycin, 1µM CCCP, and a mixture of .5µM rotenone and .5µM antimycin A. *: p<.05 by Two Way
ANOVA compared to control.
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4.4 Discussion
4.4.1 Astrocyte Arsenic Detoxification is Dependent upon GSH Biosynthesis and MRP1
The preliminary data from the Dr Annadurai Anandhan indicated that lethal arsenic
exposure causes GSH depletion, and that sub-lethal arsenic exposure increases the intracellular
GSH content, in agreement with previous observations (Sagara et al., 1996;Koehler et al., 2014).
Whether this loss of intracellular GSH was principally due to a net loss of intracellular GSH, or
was being oxidized in a transitory, recyclable process remained to be determined. With 6-AN
having a minimal effect, and BSO having such a dramatic effect on astrocyte viability, we are
confident that GSH is being lost in a process related to arsenic exposure, either by formation of an
As-GSX complex and/or by the direct efflux of GSH from the astrocytes.
While As-GSX complex efflux has not been directly demonstrated in astrocytes to our
knowledge, both GSH efflux (Hirrlinger et al., 2002;Hirrlinger and Dringen, 2005) and arsenic
induced GSH efflux (Tadepalle et al., 2014) have been linked to MRP1 in astrocytes. We did not
observe an increase in intracellular GSH with MRP1 inhibition (data not shown). The use of a
time-course ICP-MS to quantify intracellular arsenic accumulation during arsenic exposure with
and without MK571 provided two important pieces of information: (1) sodium arsenite
concentrations can be divided into sub-lethal (5 µM), steady state (10 µM), and lethal (20 µM)
dosages, and (2) reinforces that MRP1 inhibition directly increased arsenic accumulation within
the astrocytes and sensitizes astrocytes to arsenic. This information allowed us to narrow
subsequent experiments around the 10 µM exposure, and provided further evidence that MRP1 is
directly or indirectly involved in the export of arsenic and not just GSH export for neuronal use.
The increased arsenic accumulation with MK571 had been previously reported, but the prior
study performed the measurement after a two hour exposure (Tadepalle et al., 2014), which our
data indicates is within an acute response phase of arsenic exposure. We believe our results
strengthen prior observations, and provide a foundation for the exploration of arsenic
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accumulation at the later, chronic stages of exposure. Combined with the BSO/6-AN data, we
believe that a glutathionylated arsenical, or an arsenical that relies on GSH as a co-substrate, is
exported in an MRP1 dependent process.

4.4.2 Arsenic Exposure Induces Excitotoxic Glutamate Accumulation in Astrocyte Cultures
To our knowledge, a metabolomic profile comparison of primary cortical astrocytes with
variable arsenic exposure has not been performed. Tracking the changes in carbon labeling
allowed insights into how metabolism shifted in response to arsenic toxicity. Intracellular
glutamate labeling depleted with increasing arsenic, while the opposite was observed
extracellularly (Figure 4.2B and Figure 4.5A). Importantly, 13C-labeled glutamate was
distinguishable from glutamine, which is the expected product of astrocytes for neurotransmitter
recycling. The finding that glutamate was significantly produced from a glucose carbon source
and was exported has profound implications for neurotransmission and neuronal viability. The
NMR experiments only provided estimates of relative metabolite concentration changes.
Validation of the NMR glutamate efflux was performed by the Glutamate-Glo enzymatic
kit, where arsenic treated astrocytes demonstrated a very high rate of glutamate production. As
the DMEM:f12 media used in our experiments had ~50 µM of glutamate as part of its
formulation (validated with a preliminary test of the DMEM:f12 media with Glutamate-Glo, data
not shown), we utilized Neurobasal A medium supplemented with B27 and 2.5 mM glutamine (to
match DMEM:f12 glutamine) in order to quantify astrocyte produced glutamate. Our results
contrast with a previous report that found an approximate 1.5 µM increase in extracellular
glutamate after a 24hr exposure of 10 µM sodium arsenite to primary cortical astrocyte cultures
(Wang et al., 2012). At the same arsenic exposure, we repeatedly observed over 30 µM glutamate
within the media. In fact, an exposure of only 5 µM of sodium arsenite yielded ~ 20 µM
glutamate in the media. A Glutamate-Glo experiment was also performed with astrocytes in our

95
DMEM:f12 media (data not shown), showing that a 10 µM sodium arsenite treatment produced
an additional 25 µM of glutamate over background. The extracellular space within the CNS has
been measured to contain ~0.6 µM glutamate. Furthermore, excitotoxic effects have been
observed in neurons cultured independently of astrocytes or in brain regions, like the
hippocampus, at an extracellular glutamate concentration of 2-5 µM (Lipton and Rosenberg,
1994;Mark et al., 2001;Chen and Lipton, 2006). Thus, our results have profound implications for
neuronal viability.
Initially, the extracellular glutamate was believed to be derived from the GSH or As-GSX
complexes that efflux from MRP1, as ɣGT has been described as a means to recycle glutamate
for GSH resynthesis in cancer cells during drug treatment (Rajpert-De Meyts et al.,
1992;Hochwald et al., 1996;Pompella et al., 2006;Ramsay and Dilda, 2014). But, the GlutamateGlo results for acivicin and MK571 indicate that GSH or As-GSX are not the source (Figure
4.5A). One limitation of the acivicin experiment (Figure 4.5A) is the lack of a positive control to
ensure its functionality. Nevertheless, it stands to reason that arsenic induced extracellular
glutamate accumulation is due to a deficiency of astrocyte glutamate reuptake, and/or an
induction of glutamate efflux that is not dependent on MRP1/ ɣGT.
Two principal glutamate reuptake transporters in astrocytes are EAAT1/2, with a high
localization near the synaptic cleft and capillary processes (Roberts et al., 2014), and the reversal
of glutamate transport during membrane depolarization (Szatkowski et al., 1990). Crystal
structures have shown that UCPH-101 inhibits EAAT1 allosterically by preventing the substrate
translocation transition state (Canul-Tec et al., 2017), while WAY213613 is a competitive
inhibitor of EAAT2 (Dunlop et al., 2005). Our results indicate that extracellular glutamate
accumulation dramatically increases in the presence of EAAT1/2 inhibition (Figure 4.5B).
Interestingly, extracellular glutamate significantly accumulated with EAAT1/2 inhibition
independent of arsenic, which implies the process that causes glutamate loss in astrocytes is
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active in a non-stress state. Furthermore, the results suggest that either EAAT1/2 counteracted
this process or the inhibitors reverse glutamate transport in astrocytes.
Another source of glutamate extrusion is the cystine/glutamate antiporter xCT. Cysteine
has been described as the limiting substrate of GSH synthesis in many cell types, including
astrocytes (Wang and Cynader, 2000;McBean, 2017). Astrocytes have also been found to
preferentially utilize cystine over cysteine for GSH synthesis (Kranich et al., 1996). Accordingly,
xCT may increase its activity to export glutamate to acquire cystine for this process. As shown in
Figure 4.5D, SAS has a minor but significant sensitizing effect to arsenic in astrocytes. We also
demonstrated that increasing the extracellular cystine or methionine concentrations did not alter
astrocyte sensitivity to arsenic (Appendix Figure 2A).

4.4.3 Mitochondrial Function is Integral to Astrocyte Viability in the Presence of Arsenic
While our results do not reveal the means of glutamate efflux, the data strongly
demonstrate a role for mitochondrial metabolism during arsenic exposure in astrocytes. The NMR
experiments revealed the increased integration of glucose carbons into citrate and glutamate pools
(Figure 4.2), which suggested mitochondrial metabolism must be involved. However, whether
the increased glucose carbon integration into metabolic pathways for citrate and glutamate was
serving a critical function during arsenic exposure remained unknown. We demonstrated that
mitochondrial toxins (PQ) and complex I inhibition (Rotenone, MPP+) sensitized astrocytes to
arsenic, and that astrocytes remained viable in the presence of these inhibitors in the absence of
arsenic (Figure 4.6A). A previous study demonstrate that astrocytes are not dependent on Cox10
in an in vivo model (Supplie et al., 2017). Thus, we do not believe this sensitization is due to a
deficiency in OXPHOS derived ATP. Co-administration of rotenone and 10/20 µM arsenic did
result in a net decrease of 20% in the total ATP, though no differences were observed with either
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independent treatment (Figure 4.6B). We can also conclude that pyruvate carbon entry into the
mitochondria is required during arsenic exposure in astrocytes (Figure 4.6C).
While it is clear that the mitochondria perform an integral function during arsenic
exposure, the precise role cannot be definitively determined by our data. Nevertheless, our
observations do allow for identifying potential mitochondrial functions critical for astrocytes
during arsenic exposure.
One possible response to arsenic exposure is the use of complex I to balance the
NAD+/NADH ratio in the cytosol. Cancer cells have long been known to metabolize glucose to
lactate (Warburg, 1956), and have demonstrated that their mitochondria were not required for
ATP production (King and Attardi, 1989). The cancer cell proliferation reduction caused by
oligomycin (an inhibitor of ATP synthetase) was shown to be reversed by low doses of the
uncoupling agent FCCP (Sullivan et al., 2015). Additionally, cancer cells treated with complex
I/III inhibitors (phenformin + piericidin/antimycin) demonstrated a metabolic shift that was
dependent on exogenous pyruvate and a reversal of MDH1 and GOT1 directionality toward the
production of aspartate (Birsoy et al., 2015). These experiments illustrated that NAD+/NADH
balancing was a key mitochondrial function in cancer cells. FCCP allowed ETC activity to
resume by removing mitochondrial hyper-polarization and exogenous pyruvate converting to
lactate bioenergetically balanced the reductive MDH1/GOT1 path of aspartate synthesis. In a
similar fashion, astrocytes may require complex I to regenerate NAD+ from NADH, as the
-ketoglutarate from acetyl-CoA and oxaloacetate in the oxidative arm of the TCA
cycle generates NADH from NAD+. Additionally, while the full conversion of glucose to lactate
does not perturb the NAD+/NADH ratio, our NMR data demonstrate that some proportion of
glucose carbons become glutamate, changing the NAD+/NADH ratio by reducing NAD+ to
NADH via isocitrate dehydrogenase. Therefore, complex I in the mitochondria of astrocytes may
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primarily act as an electron sink during arsenic exposure in order to maintain the NAD+/NADH
ratio by oxidizing NADH to NAD+ rather than to generate ATP.
The loss of viability during arsenic exposure when administering UK5099 or etomoxir
indicates that carbon entry into the mitochondria is vital. Unlike cancer cell studies (Birsoy et al.,
2015;Sullivan et al., 2015), glutamate rather than aspartate seems to be the destination for the
pyruvate carbons entering the mitochondria. Citrate has been previously observed as an
alternative carbon entry into the mitochondria for astrocytes (McKenna et al., 1995;Vogel et al.,
1998)) (Figure 3.1 and 3.2). Besides Seahorse related assays, very few studies have applied
UK5099 to astrocytes, presumably because these prior studies suggest that UK5099 does not have
an effect on astrocytes (Divakaruni et al., 2017;Weightman Potter et al., 2019). Nevertheless,
applications of UK5099 to other cell types have successfully highlighted the compensatory
mechanisms utilized for carbon entry into the mitochondria. These compensatory mechanisms
include upregulation of fatty acid oxidation (Vacanti et al., 2014), an increase in
glutamate/glutamine metabolism (Vacanti et al., 2014;Yang et al., 2014;Gray et al., 2015), and
pyruvate-alanine interconversion (McCommis et al., 2015). However, the cell types were not
glycolytic or were highly proliferative, which is unlike astrocytes. Additionally, astrocytes are
sensitive to ammonia toxicity caused by mitochondrial glutamine metabolism (Pichili et al.,
2007). Our preliminary BPTES results also indicate that glutaminase is not a vital process
(Appendix Figure 2B). It is possible that by restricting a single mitochondrial carbon source,
partial compensation could be achieved by upregulating the other mitochondrial carbon import
pathways. This could be why the UK5099, etomoxir, and AOAA results had nearly equivalent
effects on cell viability: the loss of one carbon source is compensated by the other sources.
The effect of etomoxir could be an indicator that fatty acid oxidation (FAO) is vital. FAO
is purported to be the source of acetyl-CoA, has already been demonstrated to be active in
astrocytes (Edmond et al., 1987;Ebert et al., 2003), and astrocytes restrict pyruvate
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dehydrogenase complex activity with extensive phosphorylation (Halim et al., 2010). FAO
produces significant amounts of NADH and FADH2, which creates a need for an electron sink in
order to maintain NAD+/NADH and FAD/FADH2 bioenergetic balancing. The role of the
mitochondrial electron transport chain during arsenic exposure may be to maintain this
bioenergetics balance. To further explore this hypothesis, we utilized Seahorse Mito Stress Test
to determine the oxygen consumption rate of astrocyte mitochondria (Figure 4.7). In the presence
of etomoxir and independent of arsenic, we observed minimal basal oxygen consumption and a
minimal effect of oligomycin treatment. However, application of CCCP demonstrated that the
electron transport chain was still functional and at a level similar to control cells. One possible
interpretation is that the ETC normally acts to balance the bioenergetic disturbance of FAO, but
the removal of mitochondrial FAO effectively eliminates the majority of the ETC’s purpose.
However, arsenic exposure requires a mitochondrial process that uses glucose and fatty acid
carbon inputs. Thus, the loss of FAO leads to the observed reduction in viability.
Inhibition of transamination processes by AOAA causes a similar loss in viability during
arsenic exposure as seen with UK5099 and etomoxir. However, transamination participates in
both bioenergetic balancing and biosynthesis, and is not restricted to mitochondrial processes.
Previous reports on astrocytes have shown that AOAA restricts the metabolism and synthesis of
glutamate from TCA cycle intermediates (Westergaard et al., 1996;Sonnewald et al., 1997).
Further studies highlighted that glutamine synthesis required aspartate (Pardo et al., 2011), further
reinforcing the potential role of transamination for glutamate synthesis (McKenna et al., 2016).
On the other hand, astrocytes upregulate glucose and lactate metabolism in the presence of 5 mM
AOAA, indicating that the malate-aspartate shuttle is not the mechanism of electron balance in
astrocytes (McKenna et al., 1993). This observation doesn’t outright disprove the hypothesis that
the ETC is being used for bioenergetic balancing. The glycerol 3-phosphate shuttle has been
implicated in astrocytes (McKenna et al., 1993;Waagepetersen et al., 2001), though more
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verification is required due to discrepancies in the shuttle’s expression in astrocytes (McKenna et
al., 2006). This argues in favor of our AOAA results being related to aminotransferase inhibition
in regards to glutamate synthesis, and, therefore; that de novo glutamate synthesis is crucial for
astrocyte viability. However, we did not observe a decrease in extracellular glutamate
accumulation in the presence of AOAA (Figure 4.6E), which argues against this idea, but we did
observe that AOAA increased arsenic accumulation within astrocytes (Figure 4.6D). This result
indicates that a transamination process is involved in arsenic detoxification.
While the glucose NMR results (Figure 4.2) require further analysis and supplemental
experimentation to make definitive conclusions, we can speculate as to what the currently
observed metabolite trends indicate. The reduction in UDP-glucose at all arsenic concentrations is
an indication that glycogenesis is being downregulated in the presence of arsenic. This is
supported by previous studies that described glucose consumption and lactate production to
increase during acute arsenic toxicity (Tadepalle et al., 2014). While the intracellular lactate level
did not significantly change (with the exception of the highest arsenic concentrations tested), we
observed an increase in the extracellular lactate excretion at sublethal arsenic exposure.
Extracellular citrate followed a similar trend as lactate, indicating that increased glucose
utilization is feeding both cytosolic and mitochondrial pathways. Fructose-6-phosphate decreased
at sublethal arsenic levels, remained equivalent at equilibrium concentrations, and rose at lethal
doses. Conversely, 3-phosphoglycerate levels increased for all arsenic concentrations tested
(Figure 4.2A). The 6-AN viability results (Figure 4.3A) suggest cytosolic NADPH is not a
limiting resource during arsenic exposure. Metabolomic studies in other cell types studying ROS
and PPP induction found that upper glycolysis intermediates (such as fructose-6-phosphate)
increase, while lower glycolysis intermediates (such as 3-phosphoglycerate) decrease (Kuehne et
al., 2015;Lucarelli et al., 2015). Since sublethal arsenic exposure exhibits an opposite trend and
we did not identify changes in PPP intermediates, glycolysis may be preferred over PPP during
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arsenic toxicity. However, that does not explain why the fructose-6-phosphate trend reverses at
lethal arsenic concentrations.
Interestingly, the preliminary glutamate NMR results (Appendix Figure 3) show that
extracellular glutamate levels increased during arsenic exposure, which corroborates our findings
from the glucose NMR (Figure 4.2) and the Glutamate-Glo experiments (Figure 4.5A and
Figure 4.6E). The extracellular lactate levels did not change, indicating that glutamate
metabolism did not change. Surprisingly, GSH levels did not increase with arsenic, which we
would have expected given the requirement for GSH synthesis during arsenic exposure (Figure
4.3B). It is possible that glutamate is not a limiting reagent for GSH synthesis (that it is cysteine
instead), and that glutamate is being utilized for another, undefined process in astrocytes during
arsenic exposure.

4.5 Conclusions
We can conclusively demonstrate that arsenic detoxification in astrocytes requires GSH
synthesis and MRP1. We also demonstrate that in the presence of arsenic, astrocytes synthesize
glutamate from glucose precursors and efflux glutamate into the extracellular space to
concentrations beyond what is considered the excitotoxicity threshold for most glutamatergic
neurons. We further show that inhibition of EAAT1/2 causes an increase in extracellular
glutamate independently of arsenic, and that EAAT1, but not EAAT2, inhibition sensitizes
astrocytes to arsenic. Additionally, we demonstrate that the mitochondria perform a critical, yet
undefined, function in astrocytes exposed to arsenic, and that inhibition of the mitochondrial
pyruvate carrier or transamination processes sensitizes astrocytes to arsenic (Figure 4.8).
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Figure 4.8: Essential Tested Metabolic Pathways during Arsenic Exposure
Model of astrocyte metabolism. (A) Astrocytes remain viable during chemical inhibition of mitochondrial
metabolism, and mechanisms of GSH synthesis and glutamate transport. (B) During arsenite exposure,
mitochondrial metabolism, GSH synthesis, and glutamate transport become essential for survival, in
addition to the activity of MRP1. Glutamate accumulates extracellularly to excitotoxic concentrations
during arsenite exposure by a yet determined mechanism. (?): The role of transamination requires further
characterization, and cannot be definitely linked to glutamate synthesis.
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CHAPTER 5
CONCLUSIONS AND FUTURE EXPERIMENTS

Chapters 2 and 3 provide in depth explorations of current literature highlighting the
complexity and interconnectedness of the cells of the central nervous system, and the specialized
metabolic functions of astrocytes, with an emphasis on mitochondrial function. In chapter 4,
experiments were performed to explore the alteration of astrocyte metabolism when challenged
with the xenobiotic arsenic. The results of these experiments show that astrocytes were shown to
be dependent upon de novo glutathione (GSH) synthesis during arsenic exposure. A time course
of intracellular arsenic accumulation at various arsenic concentrations illustrated that there was an
acute phase accumulation of arsenic in astrocytes, followed by an adaptive chronic phase where
arsenic accumulation was halted or reversed at sub-lethal sodium arsenite concentrations. Further,
inhibition of the multidrug resistance protein 1 (MRP1) led to an accumulation of intracellular
arsenic in astrocytes and sensitized astrocytes to arsenic. Arsenic exposure led to an accumulation
of glutamate in the media of astrocyte cultures, an effect exacerbated by the inhibition of
excitatory amino acid transporters 1 and 2 (EAAT1/2). Additionally, application of mitochondrial
toxins or inhibition of carbon inputs to the mitochondria or transamination processes sensitized
astrocytes to arsenic. The relevance of each of these results is briefly covered below.
Arsenic exposure requires de novo synthesis of GSH to maintain astrocyte viability,
illustrating that the reduction of existing oxidized glutathione (GSSG) pools is insufficient to
maintain astrocyte viability and REDOX homeostasis in the presence of arsenic. Cellular and
DNA damage from reactive oxygen species (ROS) has been observed during arsenic exposure in
other cell types (Hei et al., 1998;Liu et al., 2001). While low dose arsenic does not generate
detectable ROS in viable astrocytes (Catanzaro et al., 2010), it should be noted that astrocyte
intracellular GSH content does not significantly change at the same low doses after 24hrs (Zhao
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et al., 2012). This thesis reinforces that arsenic induced ROS is not a significant factor by
illustrating that 6-aminonicotinamide (6-AN), an inhibitor of the pentose phosphate pathway
(PPP), has no significant effect on arsenic sensitization in astrocytes, while inhibition of GSH
synthesis by L-buthionine-sulfoximine (BSO) profoundly sensitized the astrocytes to arsenic.
The generation of a time course of intracellular arsenic accumulation at low doses was
important to illustrate that the detoxification mechanisms in astrocytes exposed to arsenic are not
immediate, and that 10 µM sodium arsenite is near the limit of the detoxification capacity of
astrocytes. The time-course generated in this thesis illustrates that within the first three hours of
exposure, intracellular arsenic accumulation increases, followed by a reversal (5 µM sodium
arsenite) or cessation (10 µM sodium arsenite) of arsenic accumulation beyond that point at sublethal concentrations. The time course of 20 µM sodium arsenite does not clearly demonstrate
such a change, and the astrocytes show cell death at 48hrs at this concentration. Prior literature
illustrates that arsenic accumulation measurements in astrocytes has used either very high arsenic
concentrations (Koehler and Dringen, 2013;Koehler et al., 2014), and/or have used very short
exposure times (Koehler and Dringen, 2013;Tadepalle et al., 2014). The time course created in
this thesis demonstrates that cellular responses to xenobiotics clearly differ significantly over the
exposure time (in hours for astrocytes and arsenic), and that metabolic changes due to xenobiotic
exposure may be masked if assays are performed too quickly following exposure. Further, this the
near steady state of intracellular arsenic accumulation in astrocytes at 10 µM sodium arsenite
provide an experimental condition whereby disruptions to detoxification processes may be readily
observed in terms of viability.
The results obtained from the inhibition of MRP1 provide further evidence in the
contended role of this transporter in arsenic exposure. MRP1 has been described to efflux a
glutathionylated arsenical complex (Leslie et al., 2004;Carew et al., 2011) (reviewed in (Leslie,

112
2012)), or to co-transport arsenic and GSH out of the cell (Salerno et al., 2002). MRP1 is also
responsible for the neuroprotective export of GSH by astrocytes to neurons, reviewed in detail in
Chapters 2 and 3. Studies into the effects of MRP1 inhibition by MK571 during arsenic exposure
in astrocytes found that arsenic accumulation increased in the presence of MK571 but no effect
on astrocyte viability was observed (Meyer et al., 2013;Tadepalle et al., 2014). A separate study
found similar increases in arsenic accumulation with MK571, but observed cytotoxic effects as
well after 72hrs (Gulden et al., 2017). Our data reinforce that MRP1 inhibition leads to an
increase in intracellular arsenic accumulation and compromises cell viability.
During arsenic exposure, excitotoxic concentrations of glutamate accumulate in the
media of astrocyte cultures. As detailed in chapter 4, NMR results show that glucose carbons are
being metabolized toward the production of glutamate that principally is found in the media,
rather than within the astrocytes. Further NMR experiments are underway to better isolate the
precise metabolic pathways utilized for this glutamate production but were not ready at the time
of this thesis. A previous report that found an approximate 1.5 µM increase in extracellular
glutamate after 24hrs exposure of 10 µM sodium arsenite (Wang et al., 2012). An enzymatic
assay was performed (see chapter 4) and the extracellular glutamate observed here was
consistently above 30 µM. Glutamate is an excitatory neurotransmitter, and neuronal
excitotoxicity has been observed in the 2-5 µM glutamate range (Lipton and Rosenberg,
1994;Mark et al., 2001;Chen and Lipton, 2006). This finding has profound implications for
neuronal survival when astrocytes are exposed to arsenic. An additional quantification technique
beyond the enzymatic assay performed is warranted, given the similarity of this thesis’s
methodology and that described above (Wang et al., 2012). Further, it is important to discover
how this glutamate is released, as the mechanism may lie in a region of the astrocyte far from a
synaptic cleft (see chapter 3 for more detail). Regardless, this is a novel finding.
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This thesis begins to explore two possible mechanisms for the release of glutamate from
astrocytes. The first is by the cystine-glutamate exchanger (xCT), which effluxes glutamate to
take in cystine, a rate limiting component of GSH synthesis. Viability experiments utilizing
sulfasalazine (SAS), an inhibitor of xCT, showed a minor but significant reduction in astrocyte
viability. Experiments are planned to test if SAS significantly impacts the accumulation of
extracellular glutamate but were not completed at the time of this thesis. The second is by
reversal of EAAT1 and EAAT2 (Szatkowski et al., 1990), transporters that normally are involved
in the uptake of glutamate (see chapter 3 and 4). Inhibition of both EAAT1/2 significantly
increased the extracellular glutamate concentration, including in the absence of arsenic. This data
indicates that EAAT1/2 are not only not the source of glutamate release, but are also active to
counteract some other mechanism of glutamate release that occurs during culture conditions,
which requires further characterization. A test of extracellular glutamate quantification with
EAAT1 and EAAT2 independently inhibited is planned for future tests. Viability tests of EAAT1
and EAAT2 inhibition demonstrated that EAAT1 inhibition, but not EAAT2, sensitized
astrocytes to arsenic, indicating that EAAT1 is playing a vital function during toxicity. One
possibility is that intracellular glutamate is being depleted and must be synthesized from glucose
and/or reuptaken by EAAT1 in order to maintain GSH synthesis.
Data from this thesis demonstrates that mitochondrial metabolism is required in
astrocytes during arsenic exposure. As outlined in more detail in chapters 2-4, astrocytes are
principally glycolytic, do not require oxidative phosphorylation to perform their functions, and
are resistant to mitochondrial toxins (Bolanos et al., 1995;Almeida et al., 2001;Supplie et al.,
2017). This thesis confirmed that astrocytes remained viable in the presence of mitochondrial
toxins, but these toxins sensitized the astrocytes to arsenic, indicating that the mitochondria are
performing a vital function during arsenic exposure. The prior data from this thesis indicates that
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it may be tied to glutamate synthesis from glucose (NMR results) to synthesize GSH (BSO
results) and/or to compensate for the glutamate effluxed during arsenic exposure (NMR and
Glutamate-Glo assay). To this end, inhibition of mitochondrial carbon inputs by UK5099, an
inhibitor pyruvate entry to the mitochondria, and by etomoxir, an inhibitor of medium and long
chain fatty acid entry to the mitochondria. Similarly, inhibition of transamination, a component of
glutamate synthesis, by aminooxyacetic acid (AOAA) was tested. All three inhibitors (UK5099,
etomoxir, AOAA) significantly decreased astrocyte viability in the presence of arsenic. The
AOAA result indicates that a transamination process is involved in arsenic detoxification, and
warrants further exploration, as transamination is not limited to mitochondrial processes.
Fatty acid utilization as a mitochondrial carbon source in astrocytes is a recent subject of
research (see chapter 3), and the etomoxir results reinforce this possibility. To further characterize
this, a Mitochondrial Stress Test (Agilent) was performed in the presence of etomoxir and
arsenic. The co-administration of etomoxir and arsenic seems to cause major mitochondrial
dysfunction with a drastically reduced mitochondrial capacity for OXPHOS. This could be a sign
of mitochondrial degradation at this time point, and requires further exploration to determine the
cause. It should be noted that a 200 µM etomoxir treatment may have off target effects, since
etomoxir has been proposed to inhibit glutamine metabolism (O'Connor et al., 2018), to inhibit
complex I activity (Yao et al., 2018), and to deplete the cell of CoA (Divakaruni et al., 2018).
While the minimal basal activity of etomoxir may be due to complex I inhibition, the effect of
etomoxir on maximal respiration was minimal. To test this, the Mitochondrial Stress Test should
be repeated with just rotenone, or another complex I inhibitor, to see if the same effect was
observed. Additionally, the test should also be performed with UK5099 and AOAA.
What is clear is that a complex process occurs in astrocytes to facilitate survival in the
presence of the xenobiotic arsenic. This survival facilitation occurs in a time dependent manner
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that was not clear from prior literature results, and involves both the synthesis of GSH as well as
glutamate. Consequently, it appears that in adapting to survive in the presence of arsenic,
astrocytes may produce a toxic environment for nearby neurons. While many facets of the
metabolic response remain to be explored and characterized, it is clear that astrocytes depend
upon the biosynthetic properties of mitochondria to survive.
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APPENDIX A: Supplemental Figures

Appendix Figure 1: Viable cell population determined by flow cytometry following 48hrs of hydrogen
peroxide vs. 25µM MK571. a,b: p<.05 Two Way ANOVA vs. the untreated control (a) or the control at the
same arsenic concentration (b).
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Appendix Figure 2: (A-B) Viable cell population determined by flow cytometry following 48hrs of the
indicated arsenic vs. (A) 200µM cystine, 200µM methionine, or (B) 2µM BPTES. a: p<.05 Two Way
ANOVA vs. the untreated control (a). Note: BPTES results are preliminary, and only have 2 replicates.
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Appendix Figure 3: Preliminary 2D-NMR (1H-13C) metabolomics performed on astrocytes treated with
the indicated arsenic concentrations in DMEM containing 100µM U-13C/15N-glutamate for 24hrs.
Extracellular (A) and intracellular (B) components were measured for each sample and represented as fold
change compared to control.

